<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29962551</article-id><article-id pub-id-type="pmc">6022616</article-id><article-id pub-id-type="publisher-id">BLT.17.205153</article-id><article-id pub-id-type="doi">10.2471/BLT.17.205153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Reviews</subject></subj-group></article-categories><title-group><article-title>Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Impact &#x000e0; long terme de la vaccination des nourrissons sur la pr&#x000e9;valence de l'h&#x000e9;patite&#x000a0;B: revue syst&#x000e9;matique et m&#x000e9;ta-analyse</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Impacto a largo plazo de la inmunizaci&#x000f3;n infantil en la prevalencia de la hepatitis B: una revisi&#x000f3;n sistem&#x000e1;tica y un meta-an&#x000e1;lisis</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar"> &#x00627;&#x00644;&#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631; &#x00637;&#x00648;&#x0064a;&#x00644; &#x00627;&#x00644;&#x00623;&#x0062c;&#x00644; &#x00644;&#x00639;&#x00645;&#x00644;&#x0064a;&#x00627;&#x0062a; &#x0062a;&#x00645;&#x00646;&#x0064a;&#x00639; &#x00627;&#x00644;&#x00631;&#x00636;&#x00639; &#x00636;&#x0062f; &#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; (&#x00628;): &#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00629; &#x00645;&#x00646;&#x00647;&#x0062c;&#x0064a;&#x00629; &#x00648;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x0062a;&#x0064e;&#x00644;&#x00648;&#x0064a; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x05a74;&#x0513f;&#x0514d;&#x075ab;&#x063a5;&#x079cd;&#x05bf9;&#x04e59;&#x0809d;&#x060a3;&#x075c5;&#x07387;&#x07684;&#x0957f;&#x0671f;&#x05f71;&#x054cd;&#x0ff1a;&#x07cfb;&#x07edf;&#x07efc;&#x08ff0;&#x04e0e;&#x0835f;&#x08403;&#x05206;&#x06790;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x00414;&#x0043e;&#x0043b;&#x00433;&#x0043e;&#x00441;&#x00440;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00435; &#x00432;&#x0043b;&#x00438;&#x0044f;&#x0043d;&#x00438;&#x00435; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043c;&#x0043b;&#x00430;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00435;&#x00432; &#x0043d;&#x00430; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430; &#x00412;: &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00430;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00439; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440; &#x00438; &#x0043c;&#x00435;&#x00442;&#x00430;&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Kate Whitford et al.</alt-title><alt-title alt-title-type="title-running-head">Towards elimination of hepatitis B</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Whitford</surname><given-names>Kate</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Bette</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Micallef</surname><given-names>Joanne</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>J Kevin</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Macartney</surname><given-names>Kristine</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Van Damme</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kaldor</surname><given-names>John M</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><aff id="aff1"><label>a</label>Kirby Institute, Level 6, Wallace Wurth Building, UNSW Sydney, Kensington, <addr-line>Sydney, 2052</addr-line>
<country>Australia</country>.</aff><aff id="aff2"><label>b</label>School of Public Health and Community Medicine, UNSW Sydney, <addr-line>Sydney</addr-line>, <country>Australia</country>.</aff><aff id="aff3"><label>c</label>Sydney School of Public Health, <institution>The University of Sydney</institution>, <addr-line>Sydney</addr-line>, <country>Australia</country>.</aff><aff id="aff4"><label>d</label>National Centre for Immunisation, Research and Surveillance, <addr-line>Sydney</addr-line>, <country>Australia</country>.</aff><aff id="aff5"><label>e</label>Centre for the Evaluation of Vaccination, <institution>University of Antwerp</institution>, <addr-line>Antwerp</addr-line>, <country>Belgium</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to John Kaldor (email: <email xlink:href="jkaldor@kirby.unsw.edu.au">jkaldor@kirby.unsw.edu.au</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>14</day><month>5</month><year>2018</year></pub-date><volume>96</volume><issue>7</issue><fpage>484</fpage><lpage>497</lpage><history><date date-type="received"><day>09</day><month>11</month><year>2017</year></date><date date-type="rev-recd"><day>28</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>(c) 2018 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To conduct a systematic review and meta-analysis of the long-term impact of infant vaccination on the prevalence of hepatitis B virus (HBV) infection at the population level.</p></sec><sec><title>Methods</title><p>We searched online databases for articles reporting comparisons between population cohorts aged &#x02265;&#x02009;15 years who were exposed or unexposed to infant HBV immunization programmes. We categorized programmes as universal or targeted to infants whose mothers were positive for hepatitis B surface antigen (HBsAg). We included studies reporting prevalence of hepatitis B core antibody (HBcAb), HBsAg, or both. We evaluated the quality of the study methods and estimated the relative reduction in the prevalence of infection.</p></sec><sec><title>Findings</title><p>Of 26 studies that met the inclusion criteria, most were from China (20&#x000a0;studies). The prevalence of HBV infection in unvaccinated and universally vaccinated cohorts ranged from 0.6% (116 of 20&#x000a0;305&#x000a0;people) to 16.3% (60/367) and from 0.3% (1/300) to 8.5% (73/857), respectively. Comparing cohorts with universal vaccination to those without vaccination, relative prevalences were 0.24 (95% confidence interval, CI: 0.16&#x02013;0.35) for HBsAg and 0.23 (95% CI: 0.17&#x02013;0.32) for HBcAb. For populations with targeted vaccination, relative prevalences were 0.32 (95% CI: 0.24&#x02013;0.43) and 0.33 (95% CI: 0.23&#x02013;0.45), respectively.</p></sec><sec><title>Conclusion</title><p>The residual burden of infection in cohorts offered vaccination suggests that longer-term evaluations of vaccination coverage, timeliness and other aspects of programme quality are needed. As HBV-vaccinated infant cohorts reach adulthood, ongoing analysis of prevalence in adolescents and young adults will ensure that elimination efforts are on track.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9; </title><sec><title>Objectif</title><p>R&#x000e9;aliser une revue syst&#x000e9;matique et une m&#x000e9;ta-analyse de l'impact &#x000e0; long terme de la vaccination des nourrissons sur la pr&#x000e9;valence de l'infection par le virus de l'h&#x000e9;patite&#x000a0;B au niveau de la population.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons consult&#x000e9; des bases de donn&#x000e9;es en ligne &#x000e0; la recherche d'articles &#x000e9;tablissant des comparaisons entre des cohortes de populations &#x000e2;g&#x000e9;es de 15&#x000a0;ans ou plus ayant b&#x000e9;n&#x000e9;fici&#x000e9; ou non de programmes de vaccination contre le virus de l'h&#x000e9;patite&#x000a0;B pour les nourrissons. Nous avons divis&#x000e9; ces programmes en deux cat&#x000e9;gories: les programmes universels et les programmes cibl&#x000e9;s sur des nourrissons dont les m&#x000e8;res &#x000e9;taient positives pour l'antig&#x000e8;ne de surface de l'h&#x000e9;patite&#x000a0;B (HBsAg). Nous avons inclus des &#x000e9;tudes indiquant la pr&#x000e9;valence de l'&#x000e9;tat de l'anticorps nucl&#x000e9;ocapsidique de l'h&#x000e9;patite&#x000a0;B (HBcAb), du HBsAg ou des deux. Nous avons &#x000e9;valu&#x000e9; la qualit&#x000e9; des m&#x000e9;thodes d'&#x000e9;tude et estim&#x000e9; la diminution relative de la pr&#x000e9;valence de l'infection.</p></sec><sec><title>R&#x000e9;sultats</title><p>Sur les 26&#x000a0;&#x000e9;tudes r&#x000e9;unissant les crit&#x000e8;res d'inclusion, 20&#x000a0;provenaient de Chine. La pr&#x000e9;valence de l'infection par le virus de l'h&#x000e9;patite&#x000a0;B variait de 0,6% (116&#x000a0;individus sur 20&#x000a0;305) &#x000e0; 16,3% (60/367) chez les cohortes non vaccin&#x000e9;es, et de 0,3% (1/300) &#x000e0; 8,5% (73/857) chez les cohortes ayant b&#x000e9;n&#x000e9;fici&#x000e9; d'une vaccination universelle. La comparaison des cohortes ayant b&#x000e9;n&#x000e9;fici&#x000e9; d'une vaccination universelle avec les cohortes n'ayant re&#x000e7;u aucune vaccination a r&#x000e9;v&#x000e9;l&#x000e9; une pr&#x000e9;valence relative de 0,24 (intervalle de confiance, IC, &#x000e0;&#x000a0;95%: 0,16-0,35) pour le HBsAg et de 0,23 (IC &#x000e0; 95%: 0,17-0,32) pour le HBcAb. Dans le cas des populations ayant re&#x000e7;u une vaccination cibl&#x000e9;e, la pr&#x000e9;valence relative &#x000e9;tait de 0,32 (IC &#x000e0; 95%: 0,24-0,43) pour le HBsAg et de 0,33 (IC &#x000e0; 95&#x000a0;%: 0,23-0,45) pour le HBcAb.</p></sec><sec><title>Conclusion</title><p>La charge r&#x000e9;siduelle li&#x000e9;e &#x000e0; l'infection dans le cas de plusieurs cohortes ayant b&#x000e9;n&#x000e9;fici&#x000e9; d'une vaccination laisse entendre que des &#x000e9;valuations &#x000e0; long terme de la couverture vaccinale, du caract&#x000e8;re opportun et d'autres aspects de la qualit&#x000e9; des programmes sont n&#x000e9;cessaires. &#x000c0; mesure que les cohortes de nourrissons vaccin&#x000e9;s contre le virus de l'h&#x000e9;patite&#x000a0;B atteignent l'&#x000e2;ge adulte, une analyse continue de la pr&#x000e9;valence chez les adolescents et les jeunes adultes permettra de garantir que les efforts d'&#x000e9;limination sont sur la bonne voie.<bold/></p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Realizar una revisi&#x000f3;n sistem&#x000e1;tica y un meta-an&#x000e1;lisis del impacto a largo plazo de la vacunaci&#x000f3;n infantil sobre la prevalencia de la infecci&#x000f3;n por el virus de la hepatitis B (VHB) a nivel de la poblaci&#x000f3;n.</p></sec><sec><title>M&#x000e9;todos</title><p>Investigamos en bases de datos en Internet en busca de art&#x000ed;culos que informaran sobre comparaciones entre cohortes de poblaci&#x000f3;n con edades de &#x02265;&#x02009;15 a&#x000f1;os, que se vieron expuestas o no a programas de inmunizaci&#x000f3;n infantil del VHB. Clasificamos los programas como universales o dirigidos a menores de edad, cuyas madres dieron positivo en el ant&#x000ed;geno de superficie de la hepatitis B (HBsAg). Incluimos estudios que informan de la prevalencia del anticuerpo core de la hepatitis B (HBcAb) o del estado de HBsAg o de ambos. Evaluamos la calidad de los m&#x000e9;todos de estudio y estimamos la reducci&#x000f3;n relativa en la prevalencia de la infecci&#x000f3;n.</p></sec><sec><title>Resultados</title><p>De los 26 estudios que cumpl&#x000ed;an con los criterios de inclusi&#x000f3;n, la mayor&#x000ed;a proced&#x000ed;an de China (20&#x000a0;estudios). La prevalencia de la infecci&#x000f3;n por VHB en cohortes sin vacunar y vacunadas de forma universal variaba desde el 0,6% (116 de 20&#x000a0;305&#x000a0;personas) hasta el 16,3% (60/367) y desde el 0,3% (1/300) hasta el 8,5% (73/857), respectivamente. Al comparar las cohortes con vacunaci&#x000f3;n universal y aquellas sin vacunaci&#x000f3;n, la prevalencia relativa fue del 0,24 (intervalo de confianza del 95%, IC: 0,16&#x02013;0,35) para HBsAg y 0,23 (95% IC: 0,17&#x02013;0,32) para HBcAb. En aquellas poblaciones con vacunaci&#x000f3;n dirigida, la prevalencia relativa fue del 0,32 (95% IC: 0,24&#x02013;0,43) y del 0,33 (95% IC: 0,23&#x02013;0,45), respectivamente.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>La carga residual de la infecci&#x000f3;n que ofrece la vacunaci&#x000f3;n en diversas cohortes, sugiere que son necesarias las evaluaciones a largo plazo de la cobertura de vacunaci&#x000f3;n, del car&#x000e1;cter oportuno y de otros aspectos sobre la calidad del programa. A medida que las cohortes de ni&#x000f1;os vacunados contra el VHB alcanzan la edad adulta, un an&#x000e1;lisis continuo de la prevalencia en adolescentes y en j&#x000f3;venes asegurar&#x000e1; que los esfuerzos para su eliminaci&#x000f3;n van por buen camino.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x00647;&#x0062f;&#x00641; </title><p>&#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00629; &#x00645;&#x00646;&#x00647;&#x0062c;&#x0064a;&#x00629; &#x00648;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x0062a;&#x00644;&#x00648;&#x0064a; &#x00644;&#x00644;&#x0062a;&#x00623;&#x0062b;&#x0064a;&#x00631; &#x00637;&#x00648;&#x0064a;&#x00644; &#x00627;&#x00644;&#x00623;&#x0062c;&#x00644; &#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00631;&#x00636;&#x00639;&#x0060c; &#x00639;&#x00644;&#x00649; &#x00645;&#x0062f;&#x00649; &#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00639;&#x0062f;&#x00648;&#x00649; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; (&#x00628;) (HBV) &#x00639;&#x00644;&#x00649; &#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00644;&#x00642;&#x0062f; &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x00627;&#x00644;&#x00628;&#x0062d;&#x0062b; &#x00641;&#x0064a; &#x00642;&#x00648;&#x00627;&#x00639;&#x0062f; &#x00627;&#x00644;&#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00625;&#x00646;&#x0062a;&#x00631;&#x00646;&#x0062a; &#x00639;&#x00646; &#x00627;&#x00644;&#x00645;&#x00642;&#x00627;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00639;&#x00642;&#x0062f; &#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00627;&#x0062a; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0062a;&#x00635;&#x00644; &#x00623;&#x00639;&#x00645;&#x00627;&#x00631;&#x00647;&#x00645; &#x00625;&#x00644;&#x00649; 15 &#x00633;&#x00646;&#x00629; &#x00623;&#x00648; &#x00623;&#x00643;&#x0062b;&#x00631;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0062a;&#x00639;&#x00631;&#x00636;&#x00648;&#x00627; &#x00623;&#x00648; &#x00644;&#x00645; &#x0064a;&#x0062a;&#x00639;&#x00631;&#x00636;&#x00648;&#x00627; &#x00644;&#x00628;&#x00631;&#x00627;&#x00645;&#x0062c; &#x0062a;&#x00645;&#x00646;&#x0064a;&#x00639; &#x00627;&#x00644;&#x00631;&#x00636;&#x00639; &#x00636;&#x0062f; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; (HBV). &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x0062a;&#x00635;&#x00646;&#x0064a;&#x00641; &#x00627;&#x00644;&#x00628;&#x00631;&#x00627;&#x00645;&#x0062c; &#x00639;&#x00644;&#x00649; &#x00623;&#x00646;&#x00647;&#x00627; &#x00634;&#x00627;&#x00645;&#x00644;&#x00629;&#x0060c; &#x00623;&#x00648; &#x00645;&#x00633;&#x0062a;&#x00647;&#x0062f;&#x00641;&#x00629; &#x00644;&#x00644;&#x00631;&#x00636;&#x00639; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x00643;&#x00627;&#x00646;&#x0062a; &#x00623;&#x00645;&#x00647;&#x00627;&#x0062a;&#x00647;&#x00645; &#x00645;&#x00648;&#x0062c;&#x00628;&#x00629; &#x00644;&#x00645;&#x00633;&#x0062a;&#x00636;&#x0062f; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; (&#x00628;) &#x00627;&#x00644;&#x00633;&#x00637;&#x0062d;&#x0064a; (HBsAg). &#x00643;&#x00645;&#x00627; &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x0062a;&#x00636;&#x00645;&#x0064a;&#x00646; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00643;&#x00634;&#x00641; &#x00639;&#x00646; &#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00627;&#x00644;&#x00623;&#x0062c;&#x00633;&#x00627;&#x00645; &#x00627;&#x00644;&#x00645;&#x00636;&#x00627;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00623;&#x00633;&#x00627;&#x00633;&#x0064a;&#x00629; &#x00644;&#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; (&#x00628;) (HBcAb)&#x0060c; &#x00623;&#x00648; &#x0062d;&#x00627;&#x00644;&#x00629; HBsAg&#x0060c; &#x00623;&#x00648; &#x00643;&#x00644;&#x0064a;&#x00647;&#x00645;&#x00627;. &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x0062c;&#x00648;&#x0062f;&#x00629; &#x00637;&#x00631;&#x00642; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00629;&#x0060c; &#x00648;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00627;&#x00646;&#x0062e;&#x00641;&#x00627;&#x00636; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a; &#x00641;&#x0064a; &#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00627;&#x00644;&#x00639;&#x0062f;&#x00648;&#x00649;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00645;&#x00646; &#x00628;&#x0064a;&#x00646; 26 &#x0062f;&#x00631;&#x00627;&#x00633;&#x00629; &#x00643;&#x00627;&#x00646;&#x0062a; &#x0062a;&#x00644;&#x00628;&#x0064a; &#x00645;&#x00639;&#x00627;&#x0064a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x0064a;&#x00627;&#x00631;&#x0060c; &#x00643;&#x00627;&#x00646;&#x0062a; &#x00623;&#x0063a;&#x00644;&#x00628; &#x00627;&#x00644;&#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00645;&#x00646; &#x00627;&#x00644;&#x00635;&#x0064a;&#x00646; (20 &#x0062f;&#x00631;&#x00627;&#x00633;&#x00629;). &#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00639;&#x0062f;&#x00648;&#x00649; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; (HBV) &#x00641;&#x0064a; &#x00627;&#x00644;&#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00627;&#x0062a; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00635;&#x00646;&#x00629; &#x0060c; &#x00645;&#x00646; 0.6&#x0066a; (116 &#x00645;&#x00646; 20305 &#x00623;&#x00634;&#x0062e;&#x00627;&#x00635;) &#x00625;&#x00644;&#x00649; 16.3&#x0066a; (60/367)&#x0060c; &#x00623;&#x00645;&#x00627; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00635;&#x00646;&#x00629; &#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00627; &#x00641;&#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d;&#x0062a; &#x00645;&#x00646; 0.3&#x0066a; (1/300) &#x00625;&#x00644;&#x00649; 8.5&#x0066a; (73/857)&#x0060c; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00648;&#x00627;&#x00644;&#x0064a;. &#x00648;&#x00628;&#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00634;&#x00627;&#x00645;&#x00644; &#x00628;&#x00627;&#x00644;&#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x00644;&#x00645; &#x0062a;&#x0062d;&#x00635;&#x00644; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00637;&#x00639;&#x0064a;&#x00645;&#x0060c; &#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a; 0.24 (&#x00641;&#x00627;&#x00635;&#x00644; &#x00627;&#x00644;&#x0062b;&#x00642;&#x00629; 95&#x0066a; &#x0060c; &#x00645;&#x00646; 0.16 &#x00625;&#x00644;&#x00649; 0.35) &#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00640; HBsAg&#x0060c; &#x00628;&#x0064a;&#x00646;&#x00645;&#x00627; &#x00643;&#x00627;&#x00646; 0.23 (&#x00641;&#x00627;&#x00635;&#x00644; &#x00627;&#x00644;&#x0062b;&#x00642;&#x00629; 95&#x0066a;: 0.17 &#x00625;&#x00644;&#x00649; 0.32) &#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00640; HBcAb. &#x00623;&#x00645;&#x00627; &#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00644;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646; &#x00641;&#x0064a; &#x0062d;&#x00627;&#x00644;&#x00629; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00647;&#x0062f;&#x00641;&#x0060c; &#x00641;&#x00642;&#x0062f; &#x00643;&#x00627;&#x00646; &#x00627;&#x00644;&#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x0064a; 0.32 (&#x00641;&#x00627;&#x00635;&#x00644; &#x00627;&#x00644;&#x0062b;&#x00642;&#x00629; 95&#x0066a;: &#x00645;&#x00646; 0.24 &#x00625;&#x00644;&#x00649; 0.43)&#x0060c; &#x00648;0.33 (&#x00641;&#x00627;&#x00635;&#x00644; &#x00627;&#x00644;&#x0062b;&#x00642;&#x00629; 95&#x0066a;: 0.23 &#x00625;&#x00644;&#x00649; 0.45) &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00631;&#x0062a;&#x0064a;&#x00628;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00625;&#x00646; &#x00639;&#x00628;&#x00621; &#x00627;&#x00644;&#x00639;&#x0062f;&#x00648;&#x00649; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00628;&#x00642;&#x0064a; &#x00641;&#x0064a; &#x00639;&#x0062f;&#x00629; &#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00627;&#x0062a; &#x0062d;&#x00635;&#x00644;&#x0062a; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646;&#x0060c; &#x0064a;&#x00634;&#x0064a;&#x00631; &#x00625;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062d;&#x00627;&#x0062c;&#x00629; &#x00644;&#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645;&#x00627;&#x0062a; &#x00630;&#x00627;&#x0062a; &#x00623;&#x0062c;&#x00644; &#x00623;&#x00637;&#x00648;&#x00644; &#x0062a;&#x00634;&#x00645;&#x00644; &#x0062a;&#x0063a;&#x00637;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646;&#x0060c; &#x00648;&#x00627;&#x00644;&#x0062a;&#x00648;&#x00642;&#x0064a;&#x0062a;&#x0060c; &#x00648;&#x0063a;&#x0064a;&#x00631;&#x00647;&#x00627; &#x00645;&#x00646; &#x00627;&#x00644;&#x0062c;&#x00648;&#x00627;&#x00646;&#x00628; &#x00627;&#x00644;&#x00623;&#x0062e;&#x00631;&#x00649; &#x00644;&#x0062c;&#x00648;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c;. &#x00648;&#x00645;&#x00639; &#x00648;&#x00635;&#x00648;&#x00644; &#x00645;&#x0062c;&#x00645;&#x00648;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00631;&#x00636;&#x00639; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062d;&#x00635;&#x00644;&#x0062a; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00635;&#x0064a;&#x00646; &#x00636;&#x0062f; &#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00627;&#x00644;&#x0062a;&#x00647;&#x00627;&#x00628; &#x00627;&#x00644;&#x00643;&#x00628;&#x0062f; &#x00625;&#x00644;&#x00649; &#x00645;&#x00631;&#x0062d;&#x00644;&#x00629; &#x00627;&#x00644;&#x00628;&#x00644;&#x00648;&#x0063a;&#x0060c; &#x00633;&#x0064a;&#x00636;&#x00645;&#x00646; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00645;&#x00631; &#x00644;&#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00627;&#x00644;&#x00639;&#x0062f;&#x00648;&#x00649; &#x00628;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x00647;&#x00642;&#x0064a;&#x00646; &#x00648;&#x00627;&#x00644;&#x00634;&#x00628;&#x00627;&#x00628; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646;&#x0060c; &#x00623;&#x00646; &#x0062c;&#x00647;&#x00648;&#x0062f; &#x00627;&#x00644;&#x00642;&#x00636;&#x00627;&#x00621; &#x00639;&#x00644;&#x00649; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00639;&#x0062f;&#x00648;&#x00649; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00645;&#x00633;&#x00627;&#x00631; &#x00627;&#x00644;&#x00635;&#x0062d;&#x0064a;&#x0062d;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x05bf9;&#x05a74;&#x0513f;&#x0514d;&#x075ab;&#x063a5;&#x079cd;&#x05728;&#x07fa4;&#x04f53;&#x06c34;&#x05e73;&#x04e0a;&#x05bf9;&#x04e59;&#x0809d;&#x075c5;&#x06bd2;&#x000a0;(HBV)&#x000a0;&#x0611f;&#x067d3;&#x060a3;&#x075c5;&#x07387;&#x07684;&#x0957f;&#x0671f;&#x05f71;&#x054cd;&#x08fdb;&#x0884c;&#x07cfb;&#x07edf;&#x07efc;&#x08ff0;&#x0548c;&#x0835f;&#x08403;&#x05206;&#x06790;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x0641c;&#x07d22;&#x04e86;&#x07ebf;&#x04e0a;&#x06570;&#x0636e;&#x05e93;&#x062a5;&#x09053;&#x066fe;&#x063a5;&#x089e6;&#x0548c;&#x0672a;&#x063a5;&#x089e6;&#x05a74;&#x0513f;&#x04e59;&#x0809d;&#x075c5;&#x06bd2;&#x0514d;&#x075ab;&#x063a5;&#x079cd;&#x089c4;&#x05212;&#x07684;&#x000a0;15&#x000a0;&#x05c81;&#x04ee5;&#x04e0a;&#x04eba;&#x07fa4;&#x06bd4;&#x08f83;&#x05206;&#x06790;&#x07684;&#x06587;&#x07ae0;&#x03002;&#x02265;&#x06211;&#x04eec;&#x05c06;&#x089c4;&#x05212;&#x05206;&#x04e3a;&#x0666e;&#x0904d;&#x0578b;&#x0548c;&#x09488;&#x05bf9;&#x06bcd;&#x04eb2;&#x04e59;&#x0809d;&#x08868;&#x09762;&#x06297;&#x0539f;&#x000a0;(HBsAg)&#x000a0;&#x05448;&#x09633;&#x06027;&#x07684;&#x05a74;&#x0513f;&#x03002;&#x06211;&#x04eec;&#x07eb3;&#x05165;&#x04e86;&#x04e59;&#x0809d;&#x06838;&#x05fc3;&#x06297;&#x04f53;&#x000a0;(HBcAb)&#x000a0;&#x060a3;&#x075c5;&#x07387;&#x06216;&#x04e59;&#x0809d;&#x08868;&#x09762;&#x06297;&#x0539f;&#x000a0;(HBsAg)&#x000a0;&#x072b6;&#x06001;&#x06216;&#x04e24;&#x08005;&#x07686;&#x06709;&#x07684;&#x07814;&#x07a76;&#x03002;&#x06211;&#x04eec;&#x08bc4;&#x04f30;&#x04e86;&#x07814;&#x07a76;&#x065b9;&#x06cd5;&#x08d28;&#x091cf;&#x05e76;&#x04f30;&#x08ba1;&#x0611f;&#x067d3;&#x060a3;&#x075c5;&#x07387;&#x07684;&#x076f8;&#x05bf9;&#x07ea6;&#x07b80;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05176;&#x04e2d;&#x0ff0c;&#x06709;&#x000a0;26&#x000a0;&#x09879;&#x07814;&#x07a76;&#x07b26;&#x05408;&#x07eb3;&#x05165;&#x06807;&#x051c6;&#x0ff0c;&#x07edd;&#x05927;&#x0591a;&#x06570;&#x07814;&#x07a76;&#x06765;&#x081ea;&#x04e2d;&#x056fd;&#x0ff08;20&#x000a0;&#x09879;&#x07814;&#x07a76;&#x0ff09;&#x03002;&#x05728;&#x0672a;&#x063a5;&#x079cd;&#x075ab;&#x082d7;&#x07684;&#x04eba;&#x07fa4;&#x0548c;&#x063a5;&#x079cd;&#x0666e;&#x0904d;&#x0578b;&#x075ab;&#x082d7;&#x07684;&#x04eba;&#x07fa4;&#x04e2d;&#x0ff0c;&#x04e59;&#x0809d;&#x075c5;&#x06bd2;&#x000a0;(HBV)&#x000a0;&#x0611f;&#x067d3;&#x060a3;&#x075c5;&#x07387;&#x05206;&#x0522b;&#x05728;&#x000a0;0.6%(116/20305)&#x0548c;&#x000a0;16.3%(60/367)&#x000a0;&#x04e4b;&#x095f4;&#x04e0e;&#x000a0;0.3%(1/300)&#x000a0;&#x0548c;&#x000a0;8.5%(73/857)&#x000a0;&#x04e4b;&#x095f4;&#x03002;&#x04e0e;&#x0672a;&#x063a5;&#x079cd;&#x075ab;&#x082d7;&#x07684;&#x04eba;&#x07fa4;&#x076f8;&#x06bd4;&#x0ff0c;&#x063a5;&#x079cd;&#x0666e;&#x0904d;&#x0578b;&#x075ab;&#x082d7;&#x07684;&#x04eba;&#x07fa4;&#x07684;&#x076f8;&#x05bf9;&#x060a3;&#x075c5;&#x07387;&#x04e3a;&#x04e59;&#x0809d;&#x08868;&#x09762;&#x06297;&#x0539f;&#x000a0;(HBsAg)&#x000a0;0.24%&#x0ff08;95%&#x000a0;&#x07f6e;&#x04fe1;&#x0533a;&#x095f4;&#x0ff0c;CI&#x0ff1a;0.16-0.35&#x0ff09;&#x000a0;&#x0ff0c;&#x04e59;&#x0809d;&#x06838;&#x05fc3;&#x06297;&#x04f53;&#x000a0;(HBcAb)0.23(95%&#x000a0;CI&#x0ff1a;&#x000a0;0.17-0.32)&#x000a0;&#x03002;&#x05bf9;&#x04e8e;&#x06709;&#x09488;&#x05bf9;&#x06027;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x07684;&#x04eba;&#x07fa4;&#x0ff0c;&#x076f8;&#x05bf9;&#x060a3;&#x075c5;&#x07387;&#x05206;&#x0522b;&#x04e3a;&#x000a0;0.32(95%&#x000a0;CI&#x0ff1a;0.24-0.43&#x000a0;)&#x0548c;&#x000a0;0.33(95%&#x000a0;CI&#x0ff1a;0.23-2.3)&#x000a0;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x082e5;&#x05e72;&#x04eba;&#x07fa4;&#x04e2d;&#x063a5;&#x079cd;&#x075ab;&#x082d7;&#x07684;&#x05269;&#x04f59;&#x08d1f;&#x062c5;&#x08868;&#x0660e;&#x09700;&#x08981;&#x05bf9;&#x075ab;&#x082d7;&#x063a5;&#x079cd;&#x08986;&#x076d6;&#x07387;&#x03001;&#x053ca;&#x065f6;&#x06027;&#x0548c;&#x065b9;&#x06848;&#x08d28;&#x091cf;&#x07684;&#x05176;&#x04ed6;&#x065b9;&#x09762;&#x08fdb;&#x0884c;&#x06bd4;&#x08f83;&#x0957f;&#x0671f;&#x07684;&#x08bc4;&#x04f30;&#x03002;&#x0968f;&#x07740;&#x063a5;&#x079cd;&#x04e59;&#x0809d;&#x075c5;&#x06bd2;&#x000a0;(HBV)&#x000a0;&#x075ab;&#x082d7;&#x07684;&#x05a74;&#x0513f;&#x07fa4;&#x04f53;&#x08fdb;&#x05165;&#x06210;&#x05e74;&#x0671f;&#x0ff0c;&#x05bf9;&#x09752;&#x05c11;&#x05e74;&#x0548c;&#x05e74;&#x08f7b;&#x04eba;&#x060a3;&#x075c5;&#x07387;&#x07684;&#x06301;&#x07eed;&#x05206;&#x06790;&#x05c06;&#x0786e;&#x08ba4;&#x06d88;&#x09664;&#x04e59;&#x0809d;&#x07684;&#x052aa;&#x0529b;&#x06b65;&#x05165;&#x06b63;&#x08f68;&#x03002;<bold/></p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00441;&#x00442;&#x00438; &#x00441;&#x00438;&#x00441;&#x00442;&#x00435;&#x0043c;&#x00430;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00439; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440; &#x00438; &#x0043c;&#x00435;&#x00442;&#x00430;&#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437; &#x00434;&#x0043e;&#x0043b;&#x00433;&#x0043e;&#x00441;&#x00440;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00432;&#x0043b;&#x00438;&#x0044f;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043c;&#x0043b;&#x00430;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00435;&#x00432; &#x0043d;&#x00430; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430;&#x000a0;&#x00412;&#x000a0;(HBV) &#x0043d;&#x00430; &#x00443;&#x00440;&#x0043e;&#x00432;&#x0043d;&#x00435; &#x0043f;&#x0043e;&#x0043f;&#x00443;&#x0043b;&#x0044f;&#x00446;&#x00438;&#x00438;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00412; &#x0043e;&#x0043d;&#x0043b;&#x00430;&#x00439;&#x0043d;-&#x00431;&#x00430;&#x00437;&#x00430;&#x00445; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00430;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x00438;&#x00441;&#x0043a; &#x00441;&#x00442;&#x00430;&#x00442;&#x00435;&#x00439;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x00441;&#x0043e;&#x0043e;&#x00431;&#x00449;&#x00430;&#x00435;&#x00442;&#x00441;&#x0044f; &#x0043e; &#x00441;&#x0043e;&#x0043f;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00438; &#x0043f;&#x0043e;&#x0043f;&#x00443;&#x0043b;&#x0044f;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442;, &#x00432;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00434;&#x00435;&#x00442;&#x00435;&#x00439; &#x00432; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;&#x00435; &#x02265;&#x025a1;15&#x000a0;&#x0043b;&#x00435;&#x00442;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x00440;&#x00430;&#x0043d;&#x00435;&#x00435; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0044b; &#x00432; &#x00440;&#x00430;&#x0043c;&#x0043a;&#x00430;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00437;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043c;&#x0043b;&#x00430;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00435;&#x00432; &#x0043f;&#x00440;&#x0043e;&#x00442;&#x00438;&#x00432; HBV &#x0043b;&#x00438;&#x00431;&#x0043e; &#x0043d;&#x00435; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0044b;. &#x00410;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x0043a;&#x0043b;&#x00430;&#x00441;&#x00441;&#x00438;&#x00444;&#x00438;&#x00446;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x0043a;&#x00430;&#x0043a; &#x00443;&#x0043d;&#x00438;&#x00432;&#x00435;&#x00440;&#x00441;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00435; &#x0043b;&#x00438;&#x00431;&#x0043e; &#x0043d;&#x00430;&#x0043f;&#x00440;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043d;&#x00430; &#x0043c;&#x0043b;&#x00430;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00435;&#x00432;, &#x00443; &#x0043c;&#x00430;&#x00442;&#x00435;&#x00440;&#x00435;&#x00439; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x00431;&#x0044b;&#x0043b; &#x0043e;&#x00431;&#x0043d;&#x00430;&#x00440;&#x00443;&#x00436;&#x00435;&#x0043d; &#x0043f;&#x0043e;&#x0043b;&#x0043e;&#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00439; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430; &#x0043d;&#x00430; &#x0043f;&#x0043e;&#x00432;&#x00435;&#x00440;&#x00445;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0043d;&#x0044b;&#x00439; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00433;&#x00435;&#x0043d; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x00430; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430;&#x000a0;&#x00412;&#x000a0;(HBsAg). &#x00410;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00432;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00438;&#x0043b;&#x00438; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x00441;&#x0043e;&#x0043e;&#x00431;&#x00449;&#x00430;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x0043e; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043f;&#x0043e;&#x0043b;&#x0043e;&#x00436;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430; &#x0043d;&#x00430; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00442;&#x00435;&#x0043b;&#x00430; &#x0043a; &#x0043a;&#x00430;&#x0043f;&#x00441;&#x00438;&#x00434;&#x0043d;&#x0043e;&#x0043c;&#x00443; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00433;&#x00435;&#x0043d;&#x00443; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x00430; &#x00433;&#x00435;&#x0043f;&#x00430;&#x00442;&#x00438;&#x00442;&#x00430;&#x000a0;&#x00412;&#x000a0;(HBcAb) &#x00438;&#x0043b;&#x00438; &#x00441;&#x00442;&#x00430;&#x00442;&#x00443;&#x00441;&#x00430; &#x0043f;&#x0043e; HBsAg &#x0043b;&#x00438;&#x00431;&#x0043e; &#x0043e;&#x00431;&#x0043e;&#x00438;&#x00445; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x00435;&#x00439;. &#x00411;&#x0044b;&#x0043b;&#x00430; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00430; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430; &#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0043e;&#x00432; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00438; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00438;&#x0043d;&#x00444;&#x00435;&#x0043a;&#x00446;&#x00438;&#x00438;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00418;&#x00437; 26&#x000a0;&#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438; &#x0043a;&#x00440;&#x00438;&#x00442;&#x00435;&#x00440;&#x00438;&#x0044f;&#x0043c; &#x00432;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00431;&#x0043e;&#x0043b;&#x0044c;&#x00448;&#x00438;&#x0043d;&#x00441;&#x00442;&#x00432;&#x0043e; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x0043e; &#x00432; &#x0041a;&#x00438;&#x00442;&#x00430;&#x00435;&#x000a0;(20&#x000a0;&#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;). &#x00420;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; HBV &#x00432; &#x0043d;&#x00435;&#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00438; &#x00443;&#x0043d;&#x00438;&#x00432;&#x00435;&#x00440;&#x00441;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442;&#x00430;&#x00445; &#x00432;&#x00430;&#x00440;&#x0044c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00430; &#x0043e;&#x00442; 0,6%&#x000a0;(116 &#x00438;&#x00437; 20&#x000a0;305&#x000a0;&#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;) &#x00434;&#x0043e; 16,3%&#x000a0;(60/367) &#x00438; &#x0043e;&#x00442; 0,3%&#x000a0;(1/300) &#x00434;&#x0043e; 8,5%&#x000a0;(73/857) &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;. &#x0041f;&#x00440;&#x00438; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00438; &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442; &#x00441; &#x00443;&#x0043d;&#x00438;&#x00432;&#x00435;&#x00440;&#x00441;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439; &#x00438; &#x00431;&#x00435;&#x00437; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x00430;&#x0044f; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00430; 0,24&#x000a0;(95%-&#x00439; &#x00414;&#x00418;: 0,16&#x02013;0,35) &#x00434;&#x0043b;&#x0044f; HBsAg &#x00438; 0,23&#x000a0;(95%-&#x00439; &#x00414;&#x00418;: 0,17&#x02013;0,32) &#x00434;&#x0043b;&#x0044f; HBcAb. &#x00412; &#x0043f;&#x0043e;&#x0043f;&#x00443;&#x0043b;&#x0044f;&#x00446;&#x00438;&#x0044f;&#x00445; &#x00441; &#x00446;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00430;&#x0043f;&#x00440;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439; &#x0043e;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x00430;&#x0044f; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00430; 0,32&#x000a0;(95%-&#x00439; &#x00414;&#x00418;: 0,24&#x02013;0,43) &#x00438; 0,33&#x000a0;(95%-&#x00439; &#x00414;&#x00418;: 0,23&#x02013;0,45) &#x00441;&#x0043e;&#x0043e;&#x00442;&#x00432;&#x00435;&#x00442;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x0041e;&#x00441;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00435; &#x00431;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x00438;&#x0043d;&#x00444;&#x00435;&#x0043a;&#x00446;&#x00438;&#x00438; &#x00432; &#x0043d;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x0043b;&#x0044c;&#x0043a;&#x00438;&#x00445; &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442;&#x00430;&#x00445;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x0043c; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00430; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x0044f;, &#x00441;&#x00432;&#x00438;&#x00434;&#x00435;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x00441;&#x00442;&#x00432;&#x00443;&#x00435;&#x00442; &#x0043e; &#x00442;&#x0043e;&#x0043c;, &#x00447;&#x00442;&#x0043e; &#x0043d;&#x00435;&#x0043e;&#x00431;&#x00445;&#x0043e;&#x00434;&#x00438;&#x0043c;&#x0044b; &#x00434;&#x0043e;&#x0043b;&#x00433;&#x0043e;&#x00441;&#x00440;&#x0043e;&#x00447;&#x0043d;&#x0044b;&#x00435; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438; &#x0043e;&#x00445;&#x00432;&#x00430;&#x00442;&#x00430; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00430;&#x00446;&#x00438;&#x00435;&#x00439;, &#x00432;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00445;&#x00432;&#x00430;&#x00442;&#x00430; &#x00438; &#x00434;&#x00440;&#x00443;&#x00433;&#x00438;&#x00445; &#x00430;&#x00441;&#x0043f;&#x00435;&#x0043a;&#x00442;&#x0043e;&#x00432; &#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b;. &#x0041f;&#x0043e; &#x0043c;&#x00435;&#x00440;&#x00435; &#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x00430;&#x0043a;&#x00446;&#x00438;&#x0043d;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043e;&#x00442; HBV &#x0043a;&#x0043e;&#x00433;&#x0043e;&#x00440;&#x00442; &#x0043c;&#x0043b;&#x00430;&#x00434;&#x00435;&#x0043d;&#x00446;&#x00435;&#x00432; &#x0043f;&#x0043e;&#x00441;&#x00442;&#x0043e;&#x0044f;&#x0043d;&#x0043d;&#x0044b;&#x00439; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437; &#x00440;&#x00430;&#x00441;&#x0043f;&#x00440;&#x0043e;&#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00437;&#x00430;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x0043f;&#x0043e;&#x00434;&#x00440;&#x0043e;&#x00441;&#x00442;&#x0043a;&#x0043e;&#x00432; &#x00438; &#x0043c;&#x0043e;&#x0043b;&#x0043e;&#x00434;&#x0044b;&#x00445; &#x0043b;&#x0044e;&#x00434;&#x00435;&#x00439; &#x0043e;&#x00431;&#x00435;&#x00441;&#x0043f;&#x00435;&#x00447;&#x00438;&#x00442; &#x00443;&#x00441;&#x0043f;&#x00435;&#x00445; &#x00443;&#x00441;&#x00438;&#x0043b;&#x00438;&#x00439; &#x0043f;&#x0043e; &#x0043b;&#x00438;&#x0043a;&#x00432;&#x00438;&#x00434;&#x00430;&#x00446;&#x00438;&#x00438; &#x0044d;&#x00442;&#x0043e;&#x00439; &#x00438;&#x0043d;&#x00444;&#x00435;&#x0043a;&#x00446;&#x00438;&#x00438;.<bold/></p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Infection with the hepatitis B virus (HBV) is a major global cause of ill health that particularly affects low- and middle-income countries. An estimated 257 million people have chronic HBV infection, and 686&#x02009;000 deaths occur annually due to long-term complications including liver cirrhosis and hepatocellular carcinoma, a number that is projected to increase.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="R2" ref-type="bibr"><sup>2</sup></xref> Most chronic infection is acquired in infancy or early childhood, primarily through mother-to-child transmission.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="R4" ref-type="bibr"><sup>4</sup></xref> Exposure later in life, through sexual intercourse or blood contact, can also lead to chronic infection but more frequently results in viral clearance and immunity.</p><p>Vaccines against HBV infection are highly effective. A plasma-derived vaccine, first used in a national infant immunization programme in 1984,<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> was gradually replaced by recombinant vaccines, which can be manufactured at greater scale.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> The global recommended schedule is a dose at birth, ideally within 24 hours, followed by two to three doses at monthly intervals.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref></p><p>A few countries have reported declines in the prevalence of HBV infection following the implementation of infant vaccination programmes,<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="R9" ref-type="bibr"><sup>9</sup></xref> and declining incidence of liver cancer in children and young adults.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref><sup>&#x02013;</sup><xref rid="R14" ref-type="bibr"><sup>14</sup></xref> The World Health Organization&#x02019;s (WHO&#x02019;s) Member States aspire to the goal of global elimination of HBV infection and its consequences, with the central strategy being infant vaccination programmes to achieve direct and herd protection.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> WHO has set an elimination target of a 90% reduction in prevalence by 2030,<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> and specified two primary target indicators: cumulated incidence of HBV infection in children aged 5&#x000a0;years; and deaths from hepatocellular carcinoma, cirrhosis and chronic liver diseases attributable to HBV infection.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref></p><p>Although these two indicators effectively represent programme goals, neither are straightforward to monitor in a consistent way over time. Incidence in 5-year-olds is estimated through surveys that require the collection of specimens from a representative sample, which can be difficult to obtain in this age group.<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> Cause-specific mortality is difficult to measure reliably, particularly in countries with constrained resources. It could take decades for mortality data to fully reflect vaccine-related improvements, due to the long latency of chronic HBV infection in the causation of liver disease.</p><p>Prevalence of infection in the wider population is more straightforward to measure and is an earlier and more specific indicator of impact of immunization programmes than measuring prevalence in 5-year-olds alone. Population prevalence is also the core indicator recommended as the first priority by WHO.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> With infant vaccination now in place for several decades in several countries, it is timely to consider how well it is achieving reductions in HBV infection. This is particularly important as vaccinated generations enter adulthood, a period of higher risk of exposure through sexual activity,<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> and become the potential source of transmission to the next generation. We therefore conducted a systematic review and meta-analysis of studies assessing changes in the prevalence of HBV markers in populations offered universal or targeted infant immunization at least 15 years before.</p></sec><sec sec-type="methods"><title>Methods</title><p>This review was registered and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Registration is available at: <ext-link ext-link-type="uri" xlink:href="http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017060309">http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017060309</ext-link> (the checklist is available from the corresponding author).</p><sec><title>Search strategy</title><p>We searched the online databases of Embase&#x000ae;, MEDLINE&#x000ae;, Web of Science and LILACS to January 2017. The search terms used were: &#x0201c;hepatitis B&#x0201d; AND (&#x0201c;vaccination&#x0201d; OR &#x0201c;mass vaccination&#x0201d; OR &#x0201c;immunization&#x0201d; OR &#x0201c;immunization programmes&#x0201d;) AND (&#x0201c;adolescent&#x0201d; OR &#x0201c;adult&#x0201d;). The search was supplemented with manual searches of reference lists of articles for additional studies.</p></sec><sec><title>Inclusion criteria</title><p>We included any study addressing the long-term impact of an infant hepatitis B vaccine programme at a population level if it satisfied the following criteria: (i)&#x000a0;HBV infection status, as defined by hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg) status (or both), was assessed and reported in the study population; (ii)&#x000a0;the study population, or a specified subgroup for which data were reported separately, was aged &#x02265;&#x02009;15 years at the time when HBV infection status was assessed; (iii)&#x000a0;the study population, or a specified subgroup meeting criterion ii, included a cohort not offered vaccination through an infant programme (referred to here as the unvaccinated cohort); and (iv)&#x000a0;the study population, or a specified subgroup meeting criterion ii, included a cohort offered vaccination through an infant programme (referred to as the vaccinated cohort).</p><p>We categorized infant vaccination programmes as either universal, if hepatitis B vaccine was reported as being available to all newborns; or targeted, if vaccine was available to infants born to women screening positive for chronic HBV infection or to women at high risk for some other reason. In some countries, catch-up vaccination programmes were made available to children born a few years before implementation of universal infant vaccination. In these settings, cohorts classified as targeted may have been involved in both a targeted vaccination programme and a catch-up programme.</p><p>The primary outcomes of interest were the serological prevalences of (i)&#x000a0;HBsAg, which defines chronic HBV infection, and (ii)&#x000a0;HBcAb, which defines past, cleared HBV infection in people who are negative for HBsAg.</p><p>Two authors independently reviewed the abstracts of the studies identified by the search strategy for studies that met the inclusion criteria. Chinese language articles were translated by a third author to determine if they met the inclusion criteria. The full texts of articles that appeared to be relevant were reviewed by the two authors independently for inclusion. If the same cohort of individuals appeared to have been included in more than one publication, we contacted the authors of the articles to define overlap and avoid duplication.</p></sec><sec><title>Variables extracted</title><p>We extracted the following study variables for each eligible study, if available: study design, location (country and region); study period; participants&#x02019; age and sex distribution; vaccine programme coverage as reported in the article, including coverage of timely birth dose; number of participants in unvaccinated and vaccinated cohorts; and the number positive for HBsAg and/or HBcAb by serology testing in each cohort. We contacted the authors of the articles if data were unavailable in the original publication.</p></sec><sec><title>Quality assessment</title><p>In addition to data extraction, two authors separately reviewed the quality of each study using an adapted Cochrane method.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> We considered whether studies had addressed potential confounding variables, used a repeatable sampling frame and calculated a response rate. We also judged whether there was potential for bias through assessment of the serological markers, selective reporting of data or the representativeness of populations surveyed.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref></p></sec><sec><title>Statistical analyses</title><p>We classified studies according to outcome measures (prevalence of HBsAg, HBcAb or both) and whether they reported on universal or targeted infant vaccination programmes. We calculated the relative prevalence (RP) and corresponding 95% confidence intervals (CI) as the ratio of the prevalence in vaccinated and unvaccinated cohorts within each study. Meta-analyses were performed by pooling across studies using the Mantel&#x02012;Haenszel method. We assessed statistical heterogeneity using <italic>I<sup>2</sup></italic>, with a value of &#x0003e;&#x02009;&#x0202f;30% as the cut-off.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> A fixed-effects model was used when there was no significant heterogeneity and a random-effects model otherwise. Publication bias was evaluated visually with a funnel plot. We also conducted separate meta-analyses restricted to studies in which the comparisons involved subjects of the same age, and to determine if effects differed by HBsAg prevalence (&#x0003c;&#x02009;10% versus &#x02265;&#x02009;10%) in the unvaccinated cohort or by geographical location. All analyses were conducted using RevMan version 5.3 (Review Manager, The Cochrane Collaboration, Copenhagen, Denmark).</p></sec></sec><sec sec-type="results"><title>Results</title><p>The electronic search yielded 5781 unique articles which we screened for inclusion (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>). Of these, we assessed 114 full-text articles for eligibility and excluded 88 that were ineligible for various reasons. As three publications<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>&#x02013;</sup><xref rid="R23" ref-type="bibr"><sup>23</sup></xref> reported on the same subject group in overlapping study periods, only data from the most recent article was included.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flowchart of selection of studies for the meta-analysis of the long-term impact of hepatitis B virus immunization programmes </p></caption><graphic xlink:href="BLT.17.205153-F1"/></fig><sec><title>Study characteristics</title><p>Of the 26 studies that met the inclusion criteria (<xref rid="T1" ref-type="table">Table&#x000a0;1</xref>)<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>&#x02013;</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> most were from Taiwan, China (14 articles),<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>&#x02013;</sup><xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>&#x02013;</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref> six from mainland China,<xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="R41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="R46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> two each from the Gambia<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref> and Italy,<xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R42" ref-type="bibr"><sup>42</sup></xref> and one each from Australia<xref rid="R38" ref-type="bibr"><sup>38</sup></xref> and Fiji.<xref rid="R45" ref-type="bibr"><sup>45</sup></xref> The number of study participants aged 15 years or older varied substantially, from 259<xref rid="R37" ref-type="bibr"><sup>37</sup></xref> to 738&#x02009;195<xref rid="R40" ref-type="bibr"><sup>40</sup></xref> (median: 3776). Eleven studies included both targeted and universal vaccination cohorts,<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>&#x02013;</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref> four studies included a targeted vaccination cohort only,<xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>&#x02013;</sup><xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="R41" ref-type="bibr"><sup>41</sup></xref> while 11 studies had only a universal vaccination cohort.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="R42" ref-type="bibr"><sup>42</sup></xref><sup>&#x02013;</sup><xref rid="R46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> In virtually all studies, unvaccinated cohorts were born in years before the implementation of the newborn vaccination programme or had passed the qualifying age at the time of implementation of catch-up programmes (or both).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Summary of studies included in the meta-analysis of the long-term impact of hepatitis B virus immunization programmes</title></caption><table frame="hsides" rules="groups"><col width="72" span="1"/><col width="78" span="1"/><col width="92" span="1"/><col width="94" span="1"/><col width="47" span="1"/><col width="55" span="1"/><col width="35" span="1"/><col width="79" span="1"/><col width="121" span="1"/><col width="89" span="1"/><col width="62" span="1"/><col width="64" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Reference</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Location</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Population</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Study design</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Study period</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Study sample, no.</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Sex, %</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Vaccination programme</th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Age of cohorts, years </th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">HBsAg prevalence, %, by vaccination cohort<sup>a</sup>&#x000a0;</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Unvaccinated</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Targeted</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Universal</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lin et al., 2003<xref rid="R24" ref-type="bibr"><sup>24</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Hualien and Eastern Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">High-school students</td><td valign="top" align="left" rowspan="1" colspan="1">Repeated cross-sectional seroprevalence surveys</td><td valign="top" align="center" rowspan="1" colspan="1">1991&#x02013;2001</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;194</td><td valign="top" align="center" rowspan="1" colspan="1">M: 54; F: 46</td><td valign="top" align="left" rowspan="1" colspan="1">Targeted</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 15; targeted: 15</td><td valign="top" align="center" rowspan="1" colspan="1">12.1</td><td valign="top" align="center" rowspan="1" colspan="1">4.1</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chang et al., 2007<xref rid="R25" ref-type="bibr"><sup>25</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Taipei, China</td><td valign="top" align="left" rowspan="1" colspan="1">Students entering university</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2003&#x02013;2004</td><td valign="top" align="center" rowspan="1" colspan="1">7&#x02009;592</td><td valign="top" align="center" rowspan="1" colspan="1">M: 53; F: 47</td><td valign="top" align="left" rowspan="1" colspan="1">Targeted</td><td valign="top" align="left" rowspan="1" colspan="1">Overall mean: 19.8 (range: 16.1&#x02013;54.2)</td><td valign="top" align="center" rowspan="1" colspan="1">7.4</td><td valign="top" align="center" rowspan="1" colspan="1">2.2</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chen et al., 2007<xref rid="R26" ref-type="bibr"><sup>26</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Central Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Medical students attending university</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2000&#x02013;2003</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x02009;575</td><td valign="top" align="center" rowspan="1" colspan="1">M: 47; F: 53</td><td valign="top" align="left" rowspan="1" colspan="1">Targeted</td><td valign="top" align="left" rowspan="1" colspan="1">Overall mean: 18.7 (range: 17&#x02013;38)</td><td valign="top" align="center" rowspan="1" colspan="1">8.0</td><td valign="top" align="center" rowspan="1" colspan="1">3.6</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Da Villa et al., 2007<xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Afragola, Italy</td><td valign="top" align="left" rowspan="1" colspan="1">Residents of Afragola, Italy</td><td valign="top" align="left" rowspan="1" colspan="1">Repeated cross-sectional seroprevalence surveys</td><td valign="top" align="center" rowspan="1" colspan="1">1978 and 2006</td><td valign="top" align="center" rowspan="1" colspan="1">660<bold><sup>b</sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1">M: 51; F: 49</td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 15&#x02013;20; universal: 15&#x02013;20</td><td valign="top" align="center" rowspan="1" colspan="1">10.3</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ni et al., 2007<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Taipei city, Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Participants recruited from schools, institutes, or workplaces</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2004</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;142</td><td valign="top" align="center" rowspan="1" colspan="1">M; F<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 20&#x02013;30; targeted: 18&#x02013;19; universal: 15&#x02013;17</td><td valign="top" align="center" rowspan="1" colspan="1">10.9</td><td valign="top" align="center" rowspan="1" colspan="1">2.1</td><td valign="top" align="center" rowspan="1" colspan="1">1.5</td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Su et al., 2007<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></td><td rowspan="2" valign="top" align="left" colspan="1">Northern Taiwan, China</td><td rowspan="2" valign="top" align="left" colspan="1">New entry university students</td><td rowspan="2" valign="top" align="left" colspan="1">Cross-sectional seroprevalence survey</td><td rowspan="2" valign="top" align="center" colspan="1">2005</td><td rowspan="2" valign="top" align="center" colspan="1">1&#x02009;969</td><td rowspan="2" valign="top" align="center" colspan="1">M; F<sup>d</sup></td><td rowspan="2" valign="top" align="left" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 21+</td><td rowspan="2" valign="top" align="center" colspan="1">8.7</td><td rowspan="2" valign="top" align="center" colspan="1">3.2</td><td rowspan="2" valign="top" align="center" colspan="1">1.7</td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">Targeted: 19&#x02013;21; universal: 17&#x02013;19</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Van der Sande et al., 2007<xref rid="R30" ref-type="bibr"><sup>30</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Gambia<sup>e</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Participants in the Gambia Hepatitis Intervention Study</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2004</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;000</td><td valign="top" align="center" rowspan="1" colspan="1">M: 45; F: 55</td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 15; universal: 15</td><td valign="top" align="center" rowspan="1" colspan="1">12.1</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lin et al., 2008<xref rid="R31" ref-type="bibr"><sup>31</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Southern Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Pregnant Taiwanese women receiving prenatal examinations</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">1996&#x02013;2005</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;327</td><td valign="top" align="center" rowspan="1" colspan="1">F: 100</td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Not reported</td><td valign="top" align="center" rowspan="1" colspan="1">15.7</td><td valign="top" align="center" rowspan="1" colspan="1">11.4</td><td valign="top" align="center" rowspan="1" colspan="1">3.1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lu et al., 2009<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Central and northern Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">College and private university students</td><td valign="top" align="left" rowspan="1" colspan="1">Repeated cross-sectional seroprevalence surveys</td><td valign="top" align="center" rowspan="1" colspan="1">2000&#x02013;2007</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x02009;193</td><td valign="top" align="center" rowspan="1" colspan="1">M: 28; F: 72<sup>f</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 18; targeted: 15&#x02013;18; universal: 15&#x02013;18</td><td valign="top" align="center" rowspan="1" colspan="1">11.6</td><td valign="top" align="center" rowspan="1" colspan="1">3.5</td><td valign="top" align="center" rowspan="1" colspan="1">1.15</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sun et al., 2009<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Consecutive HIV-negative persons seeking health check-up</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2004&#x02013;2007</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x02009;594<sup>h</sup></td><td valign="top" align="center" rowspan="1" colspan="1">M: 69; F: 31</td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Overall median: 38 (range: 16&#x02013;94)</td><td valign="top" align="center" rowspan="1" colspan="1">15.5</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">8.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chen et al., 2011<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">21 universities across Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">New entry university students</td><td valign="top" align="left" rowspan="1" colspan="1">Repeated cross-sectional seroprevalence surveys</td><td valign="top" align="center" rowspan="1" colspan="1">1995&#x02013;2009</td><td valign="top" align="center" rowspan="1" colspan="1">101&#x02009;584</td><td valign="top" align="center" rowspan="1" colspan="1">M: 53; F: 47</td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Overall mean: 18.5 (range: 17.8&#x02013;20.7)</td><td valign="top" align="center" rowspan="1" colspan="1">11.8</td><td valign="top" align="center" rowspan="1" colspan="1">2.3</td><td valign="top" align="center" rowspan="1" colspan="1">1.9</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chu et al., 2011<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Northern Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Clinic attendees and university students</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2008</td><td valign="top" align="center" rowspan="1" colspan="1">2&#x02009;515</td><td valign="top" align="center" rowspan="1" colspan="1">M: 60; F: 40</td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated, mean: 41.1 targeted, mean: 22.8; universal, mean: 18.6</td><td valign="top" align="center" rowspan="1" colspan="1">16.3</td><td valign="top" align="center" rowspan="1" colspan="1">5.2</td><td valign="top" align="center" rowspan="1" colspan="1">2.8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lin et al., 2011<xref rid="R35" ref-type="bibr"><sup>35</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Central Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Undergraduate and graduate students entering university</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2005</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;677</td><td valign="top" align="center" rowspan="1" colspan="1">M; F<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 21+; targeted: 19&#x02013;21; universal: 17&#x02013;19</td><td valign="top" align="center" rowspan="1" colspan="1">11.7</td><td valign="top" align="center" rowspan="1" colspan="1">1.6</td><td valign="top" align="center" rowspan="1" colspan="1">1.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Shen et al., 2011<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Long An county, China</td><td valign="top" align="left" rowspan="1" colspan="1">Residents of five villages in Long An county</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2005</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02009;410</td><td valign="top" align="center" rowspan="1" colspan="1">M; F</td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 20&#x02013;94; universal: 15&#x02013;19</td><td valign="top" align="center" rowspan="1" colspan="1">7.1</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">5.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lai et al., 2012<xref rid="R37" ref-type="bibr"><sup>37</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Northern, central, southern and eastern Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Participants recruited into epidemiology study for vaccine-preventable diseases</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2007</td><td valign="top" align="center" rowspan="1" colspan="1">259</td><td valign="top" align="center" rowspan="1" colspan="1">M; F<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 23+; targeted: 21&#x02013;23; universal: 18&#x02013;21</td><td valign="top" align="center" rowspan="1" colspan="1">9.3</td><td valign="top" align="center" rowspan="1" colspan="1">9.4</td><td valign="top" align="center" rowspan="1" colspan="1">2.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Liu et al., 2012<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Northern Territory, Australia</td><td valign="top" align="left" rowspan="1" colspan="1">Aboriginal women giving birth in public hospitals</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2005&#x02013;2010</td><td valign="top" align="center" rowspan="1" colspan="1">5&#x02009;678</td><td valign="top" align="center" rowspan="1" colspan="1">F: 100</td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated&#x02009;mean: 27.2; universal mean: 18.0</td><td valign="top" align="center" rowspan="1" colspan="1">3.5</td><td valign="top" align="center" rowspan="1" colspan="1">2.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ni et al., 2012<xref rid="R39" ref-type="bibr"><sup>39</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Taipei city, Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Participants recruited from schools, institutes or workplaces</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2009</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;681<sup>f</sup></td><td valign="top" align="center" rowspan="1" colspan="1">M; F<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 26&#x02013;29; targeted: 24&#x02013;25; universal: 15&#x02013;23</td><td valign="top" align="center" rowspan="1" colspan="1">8.2</td><td valign="top" align="center" rowspan="1" colspan="1">4.5</td><td valign="top" align="center" rowspan="1" colspan="1">1.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Yang et al., 2012<xref rid="R40" ref-type="bibr"><sup>40</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Zhejiang province, China</td><td valign="top" align="left" rowspan="1" colspan="1">Participants of province-wide health examination plan</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2010</td><td valign="top" align="center" rowspan="1" colspan="1">738&#x02009;195</td><td valign="top" align="center" rowspan="1" colspan="1">M: 41; F: 59<sup>g</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 20+; universal: 15&#x02013;19<sup>i</sup></td><td valign="top" align="center" rowspan="1" colspan="1">7.2</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">3.5</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Zhang et al., 2012<xref rid="R41" ref-type="bibr"><sup>41</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Shanghai, China</td><td valign="top" align="left" rowspan="1" colspan="1">Infants born in 1986 from Huang Pu district, Shanghai</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2007&#x02013;2009</td><td valign="top" align="center" rowspan="1" colspan="1">1&#x02009;204</td><td valign="top" align="center" rowspan="1" colspan="1">M; F<sup>d</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Targeted</td><td valign="top" align="left" rowspan="1" colspan="1">21&#x02013;30</td><td valign="top" align="center" rowspan="1" colspan="1">14.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.6</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Boccalini et al., 2013<xref rid="R42" ref-type="bibr"><sup>42</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Tuscany, Central Italy</td><td valign="top" align="left" rowspan="1" colspan="1">Hospital outpatients in Tuscany</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence study</td><td valign="top" align="center" rowspan="1" colspan="1">2009</td><td valign="top" align="center" rowspan="1" colspan="1">762</td><td valign="top" align="center" rowspan="1" colspan="1">M: 50; F: 50</td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 31&#x02013;50; universal: 21&#x02013;30</td><td valign="top" align="center" rowspan="1" colspan="1">NA<sup>j</sup></td><td valign="top" align="center" rowspan="1" colspan="1">NA<sup>j</sup></td><td valign="top" align="center" rowspan="1" colspan="1">NA<sup>j</sup>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Peto et al., 2014<xref rid="R43" ref-type="bibr"><sup>43</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Gambia</td><td valign="top" align="left" rowspan="1" colspan="1">Participants of the Gambia Hepatitis Intervention Study born 1986&#x02013;1990</td><td valign="top" align="left" rowspan="1" colspan="1">Per-protocol analysis of cluster randomized trial</td><td valign="top" align="center" rowspan="1" colspan="1">2007&#x02013;2008</td><td valign="top" align="center" rowspan="1" colspan="1">753</td><td valign="top" align="center" rowspan="1" colspan="1">M; F<sup>d</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 17&#x02013;22; universal: 17&#x02013;22</td><td valign="top" align="center" rowspan="1" colspan="1">12.4</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">2.2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Liao et al., 2014<xref rid="R44" ref-type="bibr"><sup>44</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Guangxi Zhuang autonomous region, China</td><td valign="top" align="left" rowspan="1" colspan="1">Students from one college in Liuzhou city</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence study</td><td valign="top" align="center" rowspan="1" colspan="1">2009</td><td valign="top" align="center" rowspan="1" colspan="1">392</td><td valign="top" align="center" rowspan="1" colspan="1">M: 18; F: 82</td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 31&#x02013;50; universal: 21&#x02013;30</td><td valign="top" align="center" rowspan="1" colspan="1">12.0</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">5.3</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tsukakoshi et al., 2015<xref rid="R45" ref-type="bibr"><sup>45</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Fiji</td><td valign="top" align="left" rowspan="1" colspan="1">Residents of the central, western and northern health divisions of Fiji</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence study</td><td valign="top" align="center" rowspan="1" colspan="1">2008&#x02013;2009</td><td valign="top" align="center" rowspan="1" colspan="1">504</td><td valign="top" align="center" rowspan="1" colspan="1">M: 80<sup>k</sup>; F: 20</td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 21&#x02013;49; universal: 16&#x02013;20</td><td valign="top" align="center" rowspan="1" colspan="1">3.2</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">5.7</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chen et al., 2016<xref rid="R46" ref-type="bibr"><sup>46</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Qidong, China</td><td valign="top" align="left" rowspan="1" colspan="1">Participants of the Qidong Hepatitis B Intervention Study</td><td valign="top" align="left" rowspan="1" colspan="1">Per-protocol analysis of cluster randomized trial</td><td valign="top" align="center" rowspan="1" colspan="1">2013</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x02009;301</td><td valign="top" align="center" rowspan="1" colspan="1">M; F<sup>d</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated, mean: 26.5; universal, mean: 25.6 </td><td valign="top" align="center" rowspan="1" colspan="1">9.0</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ni et al., 2016<xref rid="R47" ref-type="bibr"><sup>47</sup></xref>&#x000a0;</td><td valign="top" align="left" rowspan="1" colspan="1">Taipei, Taiwan, China</td><td valign="top" align="left" rowspan="1" colspan="1">Participants recruited from schools, institutions and workplaces</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence survey</td><td valign="top" align="center" rowspan="1" colspan="1">2014</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02009;036</td><td valign="top" align="center" rowspan="1" colspan="1">M; F<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1">Targeted, universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 30&#x02013;50; universal: 15&#x02013;29</td><td valign="top" align="center" rowspan="1" colspan="1">7.0</td><td valign="top" align="center" rowspan="1" colspan="1">3.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Wang et al., 2016<xref rid="R48" ref-type="bibr"><sup>48</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Shenzhen, China</td><td valign="top" align="left" rowspan="1" colspan="1">Blood donors</td><td valign="top" align="left" rowspan="1" colspan="1">Cross-sectional seroprevalence study</td><td valign="top" align="center" rowspan="1" colspan="1">2005&#x02013;2014</td><td valign="top" align="center" rowspan="1" colspan="1">118&#x02009;423</td><td valign="top" align="center" rowspan="1" colspan="1">M: 67; F: 33</td><td valign="top" align="left" rowspan="1" colspan="1">Universal</td><td valign="top" align="left" rowspan="1" colspan="1">Unvaccinated: 18&#x02013;22<sup>l;</sup> universal: 18&#x02013;22<sup>l</sup></td><td valign="top" align="center" rowspan="1" colspan="1">3.89<sup>m</sup>; 0.57<sup>n</sup></td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">3.51<sup>m</sup>; 0.27<sup>n</sup></td></tr></tbody></table><table-wrap-foot><p>F:&#x02009;female; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HIV: human immunodeficiency virus; M:&#x02009;male; NA not applicable. </p><p><sup>a</sup> Targeted refers to&#x02009;infant vaccination programmes in which vaccine was available to infants born to women found on the basis of screening to have chronic HBV infection or determined to be at high risk for some other reason. Universal refers to infant vaccination programmes in which hepatitis B vaccine was reported as being available to all newborns. Unvaccinated refers to cohorts that had no universal or targeted hepatitis B immunization programmes.</p><p><sup>b</sup> We only included 15&#x02013;20 years age group from this study.</p><p><sup>c</sup> Sex distribution not reported in the article for ages &#x02265;&#x02009;15 years.</p><p><sup>d</sup> Sex distribution not reported in the article.</p><p><sup>e</sup> Region not reported in the article.</p><p><sup>f</sup> Total sex distribution for participants aged &#x02265;&#x02009;15 years.</p><p><sup>g</sup> Age distribution for all participants included in the article, aged &#x02265;&#x02009;0&#x000a0;years.</p><p><sup>h</sup> We excluded HIV-positive participants from total and calculations.</p><p><sup>i</sup> Data for ages 15&#x02013;19 years was requested and provided by authors (article only provides data for 0&#x02013;20 year age group collectively).</p><p><sup>j</sup> Article reported anti-hepatitis core antibody levels only. </p><p><sup>k</sup> Sex distribution only reported in the article for vaccinated group, age 21&#x02013;49 years.</p><p><sup>l</sup> Age range for both first-time and repeat blood donor groups.</p><p><sup>m</sup> First-time blood donors.</p><p><sup>n</sup> Repeat blood donors.</p></table-wrap-foot></table-wrap><p>Twenty studies used a single cross-sectional seroprevalence survey design,<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>&#x02013;</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref><sup>&#x02013;</sup><xref rid="R42" ref-type="bibr"><sup>42</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> four involved two or more cross-sectional seroprevalence survey time points<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref> and two were per-protocol analyses of a cluster randomized trial.<xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="R46" ref-type="bibr"><sup>46</sup></xref> Participants included university entrants,<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref><sup>,26.47,</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref> high-school students,<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> women giving birth,<xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R38" ref-type="bibr"><sup>38</sup></xref> blood donors,<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> clinic attendees seeking a health check-up,<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> hospital outpatients,<xref rid="R42" ref-type="bibr"><sup>42</sup></xref> members of population-based cohorts<xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="R46" ref-type="bibr"><sup>46</sup></xref> and participants in health screening.<xref rid="R40" ref-type="bibr"><sup>40</sup></xref> Some studies involved participants from more than one source.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref></p></sec><sec><title>Study quality</title><p>Few studies reported on participation rates for serological testing in the target populations. Those that did were conducted in institutional settings and participation rates were very high. Two studies restricted recruitment to those whose immunization history was recorded.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref> Potentially confounding variables were reported in a minority of studies, and were generally confined to age, sex and region. The sampling method appeared to be repeatable in studies based in institutions or on recruitment of blood donors, but was not clear for the other studies. There was no evidence of bias in the strategies used for serological testing or in the data selected for presentation in reports. Generalizability to wider regional or national populations was not addressed in any of the studies.</p></sec><sec><title>Prevalence of HBV markers</title><p>We analysed 21 studies reporting on HBsAg prevalence in populations exposed to universal vaccination compared with those given no vaccination (<xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>). The prevalence in the universally vaccinated cohorts ranged from 0.3%<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> to 8.5%<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> (median: 2.0%). The prevalence of HBsAg in the corresponding no vaccination cohorts were substantially higher, ranging from 0.6%<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> to 16.3%<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> (median: 9.8%). All except one study<xref rid="R45" ref-type="bibr"><sup>45</sup></xref> reported a decrease in HBsAg prevalence; the combined RP in vaccinated populations was 0.24 (95% CI: 0.16&#x02013;0.35; <xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref>). Among 15 studies that reported on HBsAg in a targeted vaccination cohort (<xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>), prevalences ranged from 0.6%<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> to 11.4%<xref rid="R31" ref-type="bibr"><sup>31</sup></xref> (median: 3.2%), compared with a range of 3.5%<xref rid="R38" ref-type="bibr"><sup>38</sup></xref> to 16.3%<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> (median: 10.9%) in the corresponding no vaccination cohorts, leading to a combined RP of 0.32 (95% CI: 0.24&#x02013;0.43; <xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>). Highly significant statistical heterogeneity between studies was found in the meta-analyses of HBsAg prevalence in studies comparing both universal and targeted vaccination with unvaccinated cohorts (<italic>I<sup>2</sup></italic>&#x02009;=&#x02009;98%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 and <italic>I<sup>2</sup></italic>&#x02009;=&#x02009;89%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively). We therefore used random-effects models to estimate combined RPs and CIs.</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Relative prevalence of hepatitis B surface antigen in the meta-analysis of the long-term impact of immunization programmes: comparison of universal vaccination and unvaccinated cohorts</p></caption><p>CI: confidence interval; df: degrees of freedom; NA: not applicable; RP: relative prevalence.</p><p><sup>a</sup> Repeat donor.</p><p><sup>b</sup> First-time donor.</p><p>Notes: The figure shows the number of participants positive for the hepatitis B surface antigen and the total number of participants in the cohort being measured. Totals may not equal the total number of participants in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>, as only age-eligible participants were included in our analysis.</p><graphic xlink:href="BLT.17.205153-F2"/></fig><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Relative prevalence of hepatitis B surface antigen in the meta-analysis of the long-term impact of immunization programmes: comparison of targeted vaccination and unvaccinated cohorts</p></caption><p>CI: confidence interval; df: degrees of freedom; NA: not applicable; RP: relative prevalence. </p><p>Notes: The figure shows the number of participants positive for the hepatitis B surface antigen and the total number of participants in the cohort being measured. Totals may not equal the total number of participants in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>, as only age-eligible participants were included in our analysis.</p><graphic xlink:href="BLT.17.205153-F3"/></fig><p>For the corresponding analyses of HBcAb prevalence, there were 13 studies that reported data from a universal vaccination cohort (<xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>), and nine that reported on targeted vaccination (<xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref>). The prevalence of HBcAb in the corresponding no vaccination cohorts ranged from 1.2%<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> to 72.1%<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> (median: 20.3%) and from 1.2%<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> to 43.9%<xref rid="R37" ref-type="bibr"><sup>37</sup></xref> (median: 22.0%), respectively. In vaccinated cohorts, prevalences were between 0.5%<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> to 27.9%<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> (median: 4.3%) for universal vaccination cohorts and 0.3%<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> to 11.3%<xref rid="R37" ref-type="bibr"><sup>37</sup></xref> (median: 7.4%) in targeted vaccination cohorts. The summary RPs for HBcAb prevalence were 0.23 (95% CI: 0.17&#x02013;0.32) for universal and 0.33 (95% CI: 0.23&#x02013;0.45) for targeted vaccination. As with the HBsAg analyses, we used random-effect models for estimates and CI due to the highly significant heterogeneity.</p><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Relative prevalence of hepatitis B core antibody in the meta-analysis of the long-term impact of immunization programmes: comparison of universal vaccination and unvaccinated cohorts </p></caption><p>CI: confidence interval; df: degrees of freedom; NA: not applicable; RP: relative prevalence. </p><p>Notes: The figure shows the number of participants positive for the hepatitis B surface antigen and the total number of participants in the cohort being measured. Totals may not equal the total number of participants in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>, as only age-eligible participants were included in our analysis.</p><graphic xlink:href="BLT.17.205153-F4"/></fig><fig id="F5" fig-type="figure" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Relative prevalence of hepatitis B core antibody in the meta-analysis of the long-term impact of immunization programmes: comparison of targeted vaccination and unvaccinated cohorts</p></caption><p>CI: confidence interval; df: degrees of freedom; NA: not applicable; RP: relative prevalence</p><p>Notes: The figure shows the number of participants positive for the hepatitis B surface antigen and the total number of participants in the cohort being measured. Totals may not equal the total number of participants in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>, as only age-eligible participants were included in our analysis.</p><graphic xlink:href="BLT.17.205153-F5"/></fig><p>Funnel plots for each of the four analyses were symmetrical around the combined RPs (<xref ref-type="fig" rid="F6">Fig.&#x000a0;6</xref>).</p><fig id="F6" fig-type="figure" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Funnel plot of publication bias in studies of the prevalence of hepatitis B virus markers in adults</p></caption><p>Hepatitis B core antibody: HBcAb; HBsAg: hepatitis B surface antigen; RP: relative prevalence; SE: standard error.</p><p>Notes: The relative prevalence is shown. Visual examination of the plot reveals symmetry of the individual studies to the combined prevalence ratio for the 22 studies.</p><graphic xlink:href="BLT.17.205153-F6"/></fig></sec><sec><title>Coverage</title><p>A birth dose of vaccine, either within 24 hours or at birth, was included in the vaccination schedule for all studies except one from Italy,<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> where birth dose was only included in the schedule for targeted vaccination. The main parameter used for coverage was administration of three doses of HBV vaccine. There was limited information on coverage for vaccinated cohorts. Five studies used self-reporting, and found coverage ranging from 55.9% (7 700 of 13 765 people) to over 98% (872/878 people).<xref rid="R25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref> Two cohort studies were able to verify the vaccination status of the entire vaccinated group.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref> One study reported 76.1% (842/1107 people) coverage of the third vaccine dose overall, but 34.5% (35/99 people) for those older than 15 years in the universal vaccination cohort and 19.0.% (10/53 people) in the targeted vaccination cohort.<xref rid="R37" ref-type="bibr"><sup>37</sup></xref></p><p>Only one study reported on timeliness of the birth dose, stating that 65 of 215 participants (30.2%) who had received the full schedule received their first dose within 24 hours.<xref rid="R44" ref-type="bibr"><sup>44</sup></xref></p><p>While some studies reported on coverage at a national or regional level, coverage was not always specified for the age group included in the review and numerators and denominators were not stated. Overall coverage of universal vaccination in Taiwan, China, as cited by some studies, was generally high, ranging from 86.9 to 98.0%.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>&#x02013;</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref> In Italy coverage was cited in the paper to have been 63% in 1991 increasing to 99% in some regions by 1996.<xref rid="R42" ref-type="bibr"><sup>42</sup></xref> In mainland China, studies cited coverage ranging from 30% in the earlier years of the vaccination programme to 99.9% in 2010.<xref rid="R40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> In the Australian study, coverage among residents of remote indigenous communities was cited to be 90%.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></p></sec><sec><title>Sub-group analyses </title><p>We also restricted analysis to the five studies that compared HBsAg prevalence between universally vaccinated and unvaccinated cohorts of the same age (<xref ref-type="fig" rid="F7">Fig.&#x000a0;7</xref>).<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref> The combined RP was 0.12 (95% CI: 0.08&#x02013;0.19) compared with 0.30 (95% CI: 0.21&#x02013;0.43) in 16 studies based on comparisons of cohorts at different ages.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R33" ref-type="bibr"><sup>33</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref><sup>&#x02013;</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref></p><fig id="F7" fig-type="figure" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Relative prevalence of hepatitis B surface antigen in the meta-analysis of the long-term impact of immunization programmes: comparison of targeted vaccination and unvaccinated cohorts with participants in the same age group</p></caption><p>CI: confidence interval; df: degrees of freedom; NA: not applicable; RP: relative prevalence.</p><p>Notes: The figure shows the number of participants positive for the hepatitis B surface antigen and the total number of participants in the cohort being measured. Totals may not equal the total number of participants in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>, as only age-eligible participants were included in our analysis. For the study of Lu et al., 2009 we included only 18-years-olds in this analysis. 15-year-olds were excluded as this group received universal vaccination.</p><graphic xlink:href="BLT.17.205153-F7"/></fig><p>Restricting analyses to those with HBsAg prevalence under 10% in the unvaccinated group yielded 10 studies, all of which assessed HBsAg positivity in cohorts with universal vaccination.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>&#x02013;</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> The combined RP was 0.34 (95% CI: 0.23&#x02013;0.52). In comparison, RP was 0.17 (95% CI: 0.12&#x02013;0.25) across the 11 studies with HBsAg prevalence of at least 10% in the unvaccinated cohort.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>&#x02013;</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="R44" ref-type="bibr"><sup>44</sup></xref> For targeted vaccination cohorts, the RP based on seven studies with HBsAg prevalence under 10% in the corresponding unvaccinated cohorts was 0.42 (95% CI: 0.32&#x02013;0.56).<xref rid="R25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>&#x02013;</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref> It was 0.24 (95% CI: 0.16&#x02013;0.36) in eight studies for which prevalence was above 10% in the unvaccinated cohorts.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R41" ref-type="bibr"><sup>41</sup></xref></p><p>Restricting analyses to studies from Taiwan, China (11 studies),<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>&#x02013;</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref> for universal vaccination cohorts, the combined RP for protection was 0.17 (95% CI: 0.12&#x02013;0.24), while for the 10 studies from other countries<xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="R38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="R43" ref-type="bibr"><sup>43</sup></xref><sup>&#x02013;</sup><xref rid="R46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="R48" ref-type="bibr"><sup>48</sup></xref> the reduction in risk was 0.36 (95% CI: 0.24&#x02013;0.54). For targeted vaccination, the RP was 0.33 (95% CI: 0&#x02219;.25&#x02013;0.44) for studies from Taiwan, China (13 studies),<xref rid="R21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref><sup>&#x02013;</sup><xref rid="R26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="R34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="R47" ref-type="bibr"><sup>47</sup></xref> with only two such studies from another area.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="R41" ref-type="bibr"><sup>41</sup></xref></p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Our meta-analysis of the long-term impact on infection of infant hepatitis B vaccination programmes at the population level focused on long-term impact by restricting the time period to at least 15 years following vaccination. An earlier review of impact did not report a combined estimate and did not specifically focus on long-term impact.<xref rid="R49" ref-type="bibr"><sup>49</sup></xref> We found that adolescents and adults in birth cohorts that were offered universal infant vaccination had a 76% lower prevalence of HBV infection and a similar reduction in risk (77%) of HBcAb prevalence compared with cohorts for whom infant vaccine programmes were unavailable. The effect was similar for both higher and lower levels of HBsAg prevalence in the unvaccinated population. The impact of targeted vaccination programmes was slightly lower (68% and 67%, respectively). As a result of overlap in the relevant cohorts, it was not possible to distinguish the effect of these programmes from the impact of catch-up programmes. It was also not possible to separate the direct effect of targeted programmes from herd effects of reduced horizontal transmission, both in vaccinated same-age peers and slightly younger universally vaccinated cohorts.</p><p>Our findings are valuable for demonstrating in a systematic way what extent of reductions in prevalence could be expected from infant HBV vaccination programmes. Most countries (184 countries in 2014)<xref rid="R50" ref-type="bibr"><sup>50</sup></xref> have implemented such programmes, but few have so far reported on long-term impact. As cohorts of adolescents and young adults are entering a period of exposure risk through sexual activity, and will become parents of the next generation, it is appropriate to measure prevalence of infection in this age group.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></p><p>The similarity between the impact on HBcAb and HBsAg suggests that the vaccine&#x02019;s mechanism of protection applies equally to preventing infection and stopping it from becoming established. Nevertheless, there was still evidence of acquisition of HBV infection in all of the vaccine-eligible populations. The most likely explanation for residual infection is incomplete vaccine coverage or non-timely vaccination.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R42" ref-type="bibr"><sup>42</sup></xref><sup>,</sup><xref rid="R45" ref-type="bibr"><sup>45</sup></xref></p><p> Studies have shown that perinatal HBV transmission is higher in infants who received the birth dose late or received fewer than the three scheduled doses.<xref rid="R51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="R52" ref-type="bibr"><sup>52</sup></xref> Global coverage of the full HBV vaccination schedule is estimated at 84%,<xref rid="R50" ref-type="bibr"><sup>50</sup></xref> while administration of the birth dose remains low at an estimated 39% in 2015.<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> The few studies in our systematic review that reported on vaccine coverage recorded highly varying rates. Most of the vaccinated cohorts from the studies in Taiwan, China, were born in the early years of the infant vaccination programme when coverage was lower. The only study reporting on administration of the birth dose within 24 hours, from mainland China, found coverage of 30.2%.<xref rid="R44" ref-type="bibr"><sup>44</sup></xref> No studies reported on the actual timing of the birth dose. Lack of timeliness of the birth dose and inadequate coverage of the full schedule are likely to have contributed to the residual infection that we found in vaccinated cohorts. Further monitoring of more recent cohorts, including reporting of timeliness of the birth dose, is needed to determine the impact of improved coverage on infection rates.</p><p>Vaccine failure, primary (no initial immune response) or secondary (waning of immunity), may have been another cause of infections in the vaccinated cohorts.<xref rid="R53" ref-type="bibr"><sup>53</sup></xref> Poor immunological response was demonstrated in reports of both active and cleared HBV infection detected among fully vaccinated people.<xref rid="R54" ref-type="bibr"><sup>54</sup></xref><sup>&#x02013;</sup><xref rid="R57" ref-type="bibr"><sup>57</sup></xref> HBV prevalence in vaccinated populations could also be attributed to mutations in the HBV S-gene, which can allow the virus to avoid being neutralized by the vaccine-generated anitbodies.<xref rid="R53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="R58" ref-type="bibr"><sup>58</sup></xref> However, while they need to be monitored, these mutants probably have little significance at a public health level and are unlikely to be a major cause of prevalence in vaccinated cohorts.<xref rid="R58" ref-type="bibr"><sup>58</sup></xref></p><p>More than half of the studies included in this meta-analysis were from Taiwan, China, reflecting a strong, early commitment to HBV prevention and research in this formerly high-prevalence area. The reduction in HBsAg prevalence was markedly higher for these studies than those in other areas (83% versus 64%). The early attainment of high newborn coverage of hepatitis B vaccine in Taiwan, China, over 95% by 2002,<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> could explain this observation.</p><p>The studies we included had limitations. Most were based on a single time-point, and compared people who had received vaccination with those who had not, on the basis of their birth cohort. As these two groups were inevitably of different ages at the time of surveying, it is not possible to remove any effect of age from the comparison. However, it is likely that most chronic infections were acquired in infancy and early childhood, and that prevalence would have been relatively stable in adolescence and adulthood, with at most a slight age-related increase. On the other hand, the estimated reduction in prevalence was 88% for the few studies that compared cohorts of the same age, as opposed to 70% in the single time-point surveys. This finding was surprising, as we might expect that studies comparing younger vaccinees to older unvaccinated cohorts would generate a more favourable estimate if there had been any increase of prevalence with age. However, comparisons involving same-age cohorts may have been affected by other, unknown confounders.</p><p>Limitations of the meta-analysis included the considerable heterogeneity in estimated effect sizes, and the statistically dominant role played by a small number of studies that contributed large numbers. Heterogeneity may have been due to differences in study designs, populations and immunization coverage, and to the characteristics identified in our assessment of study quality, such as response rates. Nevertheless all studies except one reported substantially lower HBsAg prevalence in the vaccinated cohort compared with the unvaccinated group, and the one exception reported low coverage in the vaccinated cohort.<xref rid="R45" ref-type="bibr"><sup>45</sup></xref></p><p>Another issue to consider in interpreting the findings is the relatively narrow geographical spread of studies. Although many countries have had historically high prevalence of hepatitis B, particularly in the WHO Western Pacific and African regions,<xref rid="R59" ref-type="bibr"><sup>59</sup></xref> most of the published studies that met our inclusion requirements were from China. Few studies from Africa met the inclusion criteria, so we were unable to separately assess impact in this region, where horizontal transmission is believed to play a greater role of transmission compared with Asian countries where perinatal transmission dominates.<xref rid="R60" ref-type="bibr"><sup>60</sup></xref> Determining the impact of vaccination in African countries would be important, particularly the impact of timely birth dose vaccination on reductions in prevalence in this setting. </p><p>With infant HBV vaccination programmes now widely in place, many countries could now evaluate the longer term impact on the prevalence of infection. The ideal mechanism for this evaluation is a time-series comparison with observations at regular time-points, from comparable populations. In many countries, an efficient approach is serological testing done routinely in pregnant women or other populations, such as new entrants to university, the military or other institutions. All these populations are likely to be accessible for routine, repeatable monitoring. As identified in our quality assessment, such designs should incorporate repeatable sampling frames, measure participation rates and adjust for potential confounding variables. While prevalence in 5-year-olds provides a more immediate indicator of impact, large representative samples in this age group cannot be easily accessed in many settings.</p><p>Our estimated reduction in prevalence is consistent with findings of modelling studies which suggested that routine infant vaccination from birth with global coverage of 90% could prevent 4.3 million new infections from 2015 to 2030,<xref rid="R61" ref-type="bibr"><sup>61</sup></xref> and could prevent 84% of HBV-related deaths in the hypothetical birth cohort from the year 2000.<xref rid="R61" ref-type="bibr"><sup>61</sup></xref><sup>,</sup><xref rid="R62" ref-type="bibr"><sup>62</sup></xref> Our findings strongly support the importance of the WHO target of 90% coverage of the hepatitis B vaccine in infancy,<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> as low coverage is a potential contributor to residual HBV prevalence. The evidence presented here shows that elimination is achievable, but still on the far horizon. Analyses of available serological data on HBV prevalence in adolescents and young adults can provide information on gaps in the pathway to elimination that can then be addressed through programmatic measures.</p></sec></body><back><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>National Health and Medical Research Council and Australian Government Department of Health.</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>J Kevin Yin began his involvement in this work when he was at the National Centre in Immunisation Research and Surveillance. He is a current employee of Sanofi Pasteur Australia and New Zealand, a vaccine manufacturer that does not have a hepatitis B vaccine. His involvement in this review is within his capacity of honorary lecturer of the University of Sydney only.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="web">Global hepatitis report 2017. Geneva: World Health Organization; 2017. Available from: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=94DCC044DE49C875F181513C1A4FDE5D?sequence=1">http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=94DCC044DE49C875F181513C1A4FDE5D?sequence=1</ext-link> [cited 2018 May 8].</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><collab>GBD 2013 Mortality and Causes of Death Collaborators</collab>. <article-title>Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990&#x02013;2013: a systematic analysis for the Global Burden of Disease Study 2013.</article-title>
<source>Lancet</source>. <year>2015</year>
<month>1</month>
<day>10</day>;<volume>385</volume>(<issue>9963</issue>):<fpage>117</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61682-2</pub-id><pub-id pub-id-type="pmid">25530442</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Edmunds</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Medley</surname>
<given-names>GF</given-names></string-name>, <string-name><surname>Nokes</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Hall</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Whittle</surname>
<given-names>HC</given-names></string-name>. <article-title>The influence of age on the development of the hepatitis B carrier state.</article-title>
<source>Proc Biol Sci</source>. <year>1993</year>
<month>8</month>
<day>23</day>;<volume>253</volume>(<issue>1337</issue>):<fpage>197</fpage>&#x02013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1098/rspb.1993.0102</pub-id><pub-id pub-id-type="pmid">8397416</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><article-title>Hepatitis B vaccines: WHO position paper &#x02013; July 2017.</article-title>
<source>Wkly Epidemiol Rec</source>. <year>2017</year>
<month>7</month>
<day>7</day>;<volume>92</volume>(<issue>27</issue>):<fpage>369</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">28685564</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Hsu</surname>
<given-names>NH</given-names></string-name>, <string-name><surname>Sung</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Hsu</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Hsu</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Kuo</surname>
<given-names>YT</given-names></string-name>, <etal>et al.</etal>
<article-title>A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers.</article-title>
<source>JAMA</source>. <year>1987</year>
<month>5</month>
<day>15</day>;<volume>257</volume>(<issue>19</issue>):<fpage>2597</fpage>&#x02013;<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1001/jama.1987.03390190075023</pub-id><pub-id pub-id-type="pmid">3573257</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="book"><string-name><surname>Van Damme</surname>
<given-names>PW</given-names></string-name>, <string-name><surname>Shouval</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Zanetti</surname>
<given-names>A</given-names></string-name>. <chapter-title>Hepatitis B vaccines.</chapter-title> In: <string-name><surname>Plotkin</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Orenstein</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Offit</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Edwards</surname>
<given-names>KM</given-names></string-name>, editors. <source>Plotkin&#x02019;s vaccines.</source>
<edition>7th ed.</edition>
<publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2017</year> pp. <fpage>342</fpage>&#x02013;<lpage>74</lpage>.</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="web">Table 2: Summary of WHO Position Papers &#x02013; recommended routine immunizations for children [internet]. Geneva: World Health Organization; 2017. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/immunization/policy/immunization_tables/en/">http://www.who.int/immunization/policy/immunization_tables/en/</ext-link> [cited 2018 May 8].</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Schweitzer</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Horn</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mikolajczyk</surname>
<given-names>RT</given-names></string-name>, <string-name><surname>Krause</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ott</surname>
<given-names>JJ</given-names></string-name>. <article-title>Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.</article-title>
<source>Lancet</source>. <year>2015</year>
<month>10</month>
<day>17</day>;<volume>386</volume>(<issue>10003</issue>):<fpage>1546</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)61412-X</pub-id><pub-id pub-id-type="pmid">26231459</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Wiesen</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Diorditsa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>. <article-title>Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014.</article-title>
<source>Vaccine</source>. <year>2016</year>
<month>5</month>
<day>27</day>;<volume>34</volume>(<issue>25</issue>):<fpage>2855</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.060</pub-id><pub-id pub-id-type="pmid">27020710</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Chang</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Shau</surname>
<given-names>WY</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Kong</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Liang</surname>
<given-names>DC</given-names></string-name>, <etal>et al.</etal>; <collab>Taiwan Childhood Hepatoma Study Group</collab>. <article-title>Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls.</article-title>
<source>JAMA</source>. <year>2000</year>
<month>12</month>
<day>20</day>;<volume>284</volume>(<issue>23</issue>):<fpage>3040</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1001/jama.284.23.3040</pub-id><pub-id pub-id-type="pmid">11122592</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Chien</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Jan</surname>
<given-names>CF</given-names></string-name>, <string-name><surname>Kuo</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>CJ</given-names></string-name>. <article-title>Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.</article-title>
<source>Epidemiol Rev</source>. <year>2006</year>;<volume>28</volume>(<issue>1</issue>):<fpage>126</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1093/epirev/mxj010</pub-id><pub-id pub-id-type="pmid">16782778</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Lanier</surname>
<given-names>AP</given-names></string-name>, <string-name><surname>Holck</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ehrsam Day</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Key</surname>
<given-names>C</given-names></string-name>. <article-title>Childhood cancer among Alaska Natives.</article-title>
<source>Pediatrics</source>. <year>2003</year>
<month>11</month>;<volume>112</volume>(<issue>5</issue>):<fpage>e396</fpage>. <pub-id pub-id-type="doi">10.1542/peds.112.5.e396</pub-id><pub-id pub-id-type="pmid">14595083</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Wichajarn</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kosalaraksa</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wiangnon</surname>
<given-names>S</given-names></string-name>. <article-title>Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program.</article-title>
<source>Asian Pac J Cancer Prev</source>. <year>2008</year>
<season>Jul-Sep</season>;<volume>9</volume>(<issue>3</issue>):<fpage>507</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18990029</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Qu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Zhan</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial.</article-title>
<source>PLoS Med</source>. <year>2014</year>
<month>12</month>
<day>30</day>;<volume>11</volume>(<issue>12</issue>):<fpage>e1001774</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1001774</pub-id><pub-id pub-id-type="pmid">25549238</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="web">Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva: World Health Organization; 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/">http://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/</ext-link> [cited 2018 May 8].</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="web">Global health sector strategy on viral hepatitis 2016&#x02013;2021: Towards ending viral hepatitis. Geneva: World Health Organization; 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/">http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/</ext-link> [cited 2018 May 8].</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="web">Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. Geneva: World Health Organization; 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hepatitis/publications/hep-b-c-monitoring-evaluation/en/">http://www.who.int/hepatitis/publications/hep-b-c-monitoring-evaluation/en/</ext-link> [cited 2018 May 8].</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Meheus</surname>
<given-names>A</given-names></string-name>. <article-title>Teenagers&#x02019; lifestyle and the risk of exposure to hepatitis B virus.</article-title>
<source>Vaccine</source>. <year>2000</year>
<month>2</month>
<day>18</day>;<volume>18</volume>
<issue>Suppl 1</issue>:<fpage>S26</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(99)00458-2</pub-id><pub-id pub-id-type="pmid">10683540</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="book"><string-name><surname>Higgins</surname>
<given-names>JPT</given-names></string-name>. <chapter-title>Chapter 8</chapter-title>: <chapter-title>Assessing risk of bias in included studies.</chapter-title>
<source>Cochrane handbook for systematic reviews of interventions, version 5.1.0.</source>
<publisher-loc>London</publisher-loc>: <publisher-name>The Cochrane Collaboration</publisher-name>; <year>2011</year> Available from: <ext-link ext-link-type="uri" xlink:href="http://methods.cochrane.org/bias/assessing-risk-bias-included-studies">http://methods.cochrane.org/bias/assessing-risk-bias-included-studies</ext-link> [<comment>cited 2018 May 8</comment>]. </mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Higgins</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Thompson</surname>
<given-names>SG</given-names></string-name>. <article-title>Quantifying heterogeneity in a meta-analysis.</article-title>
<source>Stat Med</source>. <year>2002</year>
<month>6</month>
<day>15</day>;<volume>21</volume>(<issue>11</issue>):<fpage>1539</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1002/sim.1186</pub-id><pub-id pub-id-type="pmid">12111919</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Kung</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>HL</given-names></string-name>. <article-title>Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan.</article-title>
<source>J Clin Virol</source>. <year>2011</year>
<month>9</month>;<volume>52</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2011.06.012</pub-id><pub-id pub-id-type="pmid">21767983</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Su</surname>
<given-names>FH</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Sung</surname>
<given-names>KY</given-names></string-name>, <string-name><surname>Jeng</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Chu</surname>
<given-names>FY</given-names></string-name>. <article-title>Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan&#x02019;s national hepatitis B vaccination programme.</article-title>
<source>J Viral Hepat</source>. <year>2008</year>
<month>1</month>;<volume>15</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18088240</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Su</surname>
<given-names>FH</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Jeng</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>CD</given-names></string-name>. <article-title>Forecasting the declining rate of chronic hepatitis-B carrier status at a Taiwanese university: twenty years after implementation of an universal HBV vaccination program in Taiwan.</article-title>
<source>Chang Gung Med J</source>. <year>2007</year>
<season>Nov-Dec</season>;<volume>30</volume>(<issue>6</issue>):<fpage>521</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18350735</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Lin</surname>
<given-names>HH</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>LY</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>LC</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>SS</given-names></string-name>, <etal>et al.</etal>
<article-title>Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan.</article-title>
<source>J Med Virol</source>. <year>2003</year>
<month>4</month>;<volume>69</volume>(<issue>4</issue>):<fpage>471</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.10333</pub-id><pub-id pub-id-type="pmid">12601753</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Chang</surname>
<given-names>HC</given-names></string-name>, <string-name><surname>Yen</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Chiu</surname>
<given-names>TY</given-names></string-name>, <string-name><surname>Jan</surname>
<given-names>CF</given-names></string-name>. <article-title>Seroprevalence of hepatitis B viral markers among freshmen &#x02013; 20 years after mass hepatitis B vaccination program in Taiwan.</article-title>
<source>J Formos Med Assoc</source>. <year>2007</year>
<month>7</month>;<volume>106</volume>(<issue>7</issue>):<fpage>513</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0929-6646(07)60001-1</pub-id><pub-id pub-id-type="pmid">17660140</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Yen</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>WY</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>SW</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Bell</surname>
<given-names>WR</given-names></string-name>, <etal>et al.</etal>
<article-title>Epidemiology of hepatitis B virus infection among young adults in Taiwan, China after public vaccination program.</article-title>
<source>Chin Med J (Engl)</source>. <year>2007</year>
<month>7</month>
<day>5</day>;<volume>120</volume>(<issue>13</issue>):<fpage>1155</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17637244</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Da Villa</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Roman&#x000f2;</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Sepe</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Iorio</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Paribello</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Zappa</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals.</article-title>
<source>Vaccine</source>. <year>2007</year>
<month>4</month>
<day>20</day>;<volume>25</volume>(<issue>16</issue>):<fpage>3133</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.044</pub-id><pub-id pub-id-type="pmid">17280750</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Ni</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Yen</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>CY</given-names></string-name>, <string-name><surname>You</surname>
<given-names>SL</given-names></string-name>, <etal>et al.</etal>
<article-title>Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies.</article-title>
<source>Gastroenterology</source>. <year>2007</year>
<month>4</month>;<volume>132</volume>(<issue>4</issue>):<fpage>1287</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2007.02.055</pub-id><pub-id pub-id-type="pmid">17433322</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Su</surname>
<given-names>FH</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Chu</surname>
<given-names>FY</given-names></string-name>. <article-title>Seroprevalence of hepatitis-B infection amongst Taiwanese university students 18 years following the commencement of a national hepatitis-B vaccination program.</article-title>
<source>J Med Virol</source>. <year>2007</year>
<month>2</month>;<volume>79</volume>(<issue>2</issue>):<fpage>138</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.20771</pub-id><pub-id pub-id-type="pmid">17177303</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>van der Sande</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Waight</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Mendy</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zaman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kaye</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sam</surname>
<given-names>O</given-names></string-name>, <etal>et al.</etal>
<article-title>Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence.</article-title>
<source>PLoS One</source>. <year>2007</year>
<month>8</month>
<day>15</day>;<volume>2</volume>(<issue>8</issue>):<fpage>e753</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0000753</pub-id><pub-id pub-id-type="pmid">17710152</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Lin</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Hsieh</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>YJ</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>YL</given-names></string-name>, <string-name><surname>Ku</surname>
<given-names>MK</given-names></string-name>, <string-name><surname>Hung</surname>
<given-names>HC</given-names></string-name>. <article-title>Hepatitis B virus infection among pregnant women in Taiwan: comparison between women born in Taiwan and other southeast countries.</article-title>
<source>BMC Public Health</source>. <year>2008</year>
<month>2</month>;<volume>8</volume>(<issue>49</issue>).<pub-id pub-id-type="doi">10.1186/1471-2458-8-49</pub-id><pub-id pub-id-type="pmid">18254978</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Lu</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Chou</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Hor</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>HL</given-names></string-name>. <article-title>Hepatitis B immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan.</article-title>
<source>Vaccine</source>. <year>2009</year>
<month>11</month>
<day>5</day>;<volume>27</volume>(<issue>47</issue>):<fpage>6613</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.08.007</pub-id><pub-id pub-id-type="pmid">19698812</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Ko</surname>
<given-names>WC</given-names></string-name>, <string-name><surname>Tsai</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>HC</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>WW</given-names></string-name>, <etal>et al.</etal>
<article-title>Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination.</article-title>
<source>Am J Gastroenterol</source>. <year>2009</year>
<month>4</month>;<volume>104</volume>(<issue>4</issue>):<fpage>877</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/ajg.2008.159</pub-id><pub-id pub-id-type="pmid">19259078</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Chu</surname>
<given-names>FY</given-names></string-name>, <string-name><surname>Su</surname>
<given-names>FH</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>YS</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>CY</given-names></string-name>, <string-name><surname>Chien</surname>
<given-names>CC</given-names></string-name>, <etal>et al.</etal>
<article-title>Hepatitis B surface antigen confirmatory testing for diagnosis of hepatitis B virus infection in Taiwan.</article-title>
<source>J Med Virol</source>. <year>2011</year>
<month>9</month>;<volume>83</volume>(<issue>9</issue>):<fpage>1514</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.22127</pub-id><pub-id pub-id-type="pmid">21739440</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Lin</surname>
<given-names>YJ</given-names></string-name>, <string-name><surname>Lan</surname>
<given-names>YC</given-names></string-name>, <string-name><surname>Wan</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>TH</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>DY</given-names></string-name>, <string-name><surname>Tsai</surname>
<given-names>CH</given-names></string-name>, <etal>et al.</etal>
<article-title>Serological surveillance and IL-10 genetic variants on anti-HBs titers: hepatitis B vaccination 20 years after neonatal immunization in Taiwan.</article-title>
<source>Clin Chim Acta</source>. <year>2011</year>
<month>4</month>
<day>11</day>;<volume>412</volume>(<issue>9-10</issue>):<fpage>766</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2011.01.006</pub-id><pub-id pub-id-type="pmid">21238445</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Shen</surname>
<given-names>LP</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>KX</given-names></string-name>, <etal>et al.</etal>
<article-title>Epidemiological changes in hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination programme.</article-title>
<source>Epidemiol Infect</source>. <year>2011</year>
<month>8</month>;<volume>139</volume>(<issue>8</issue>):<fpage>1159</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1017/S0950268810002827</pub-id><pub-id pub-id-type="pmid">21156099</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Lai</surname>
<given-names>MW</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>TY</given-names></string-name>, <string-name><surname>Tsao</surname>
<given-names>KC</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>CG</given-names></string-name>, <string-name><surname>Hsiao</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Liang</surname>
<given-names>KH</given-names></string-name>, <etal>et al.</etal>
<article-title>Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination.</article-title>
<source>Gastroenterology</source>. <year>2012</year>
<month>8</month>;<volume>143</volume>(<issue>2</issue>):<fpage>400</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2012.05.002</pub-id><pub-id pub-id-type="pmid">22580098</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Guthridge</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>SQ</given-names></string-name>, <string-name><surname>Markey</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Krause</surname>
<given-names>V</given-names></string-name>, <string-name><surname>McIntyre</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>The end of the Australia antigen? An ecological study of the impact of universal newborn hepatitis B vaccination two decades on.</article-title>
<source>Vaccine</source>. <year>2012</year>
<month>11</month>
<day>26</day>;<volume>30</volume>(<issue>50</issue>):<fpage>7309</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.033</pub-id><pub-id pub-id-type="pmid">23036497</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>Ni</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Hsu</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>HL</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>DS</given-names></string-name>. <article-title>Minimization of hepatitis B infection by a 25-year universal vaccination program.</article-title>
<source>J Hepatol</source>. <year>2012</year>
<month>10</month>;<volume>57</volume>(<issue>4</issue>):<fpage>730</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2012.05.021</pub-id><pub-id pub-id-type="pmid">22668640</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Deng</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation.</article-title>
<source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>10</issue>):<fpage>e47808</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0047808</pub-id><pub-id pub-id-type="pmid">23094094</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>
<given-names>HZ</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Su</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>MB</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>GH</given-names></string-name>, <etal>et al.</etal>
<article-title>[Valuation on the immunization efficacy on the 23 years who had received plasma-derived HBV vaccine as newborns]</article-title>. <source>Zhonghua Liu Xing Bing Xue Za Zhi</source>. <year>2012</year>
<month>2</month>;<volume>33</volume>(<issue>2</issue>):<fpage>207</fpage>&#x02013;<lpage>9</lpage>. <comment>Chinese</comment>.<pub-id pub-id-type="pmid">22575145</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><string-name><surname>Boccalini</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pellegrino</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Tiscione</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Pesavento</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Bechini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Levi</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination.</article-title>
<source>Hum Vaccin Immunother</source>. <year>2013</year>
<month>3</month>;<volume>9</volume>(<issue>3</issue>):<fpage>636</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.4161/hv.23259</pub-id><pub-id pub-id-type="pmid">23354158</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><string-name><surname>Peto</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Mendy</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Lowe</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Webb</surname>
<given-names>EL</given-names></string-name>, <string-name><surname>Whittle</surname>
<given-names>HC</given-names></string-name>, <string-name><surname>Hall</surname>
<given-names>AJ</given-names></string-name>. <article-title>Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986&#x02013;90) and in the nationwide immunisation program.</article-title>
<source>BMC Infect Dis</source>. <year>2014</year> Jan;<volume>14</volume>(<issue>7</issue>). <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Mendy%20ME%5BAuthor%5D&#x00026;cauthor=true&#x00026;cauthor_uid=24397793">https://www.ncbi.nlm.nih.gov/pubmed/?term=Mendy%20ME%5BAuthor%5D&#x00026;cauthor=true&#x00026;cauthor_uid=24397793</ext-link><pub-id pub-id-type="doi">10.1186/1471-2334-14-7</pub-id><pub-id pub-id-type="pmid">24397793</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><string-name><surname>Liao</surname>
<given-names>XY</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>ZZ</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>FB</given-names></string-name>, <string-name><surname>Qin</surname>
<given-names>HN</given-names></string-name>, <string-name><surname>Ling</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>RC</given-names></string-name>, <etal>et al.</etal>
<article-title>Seroprevalence of hepatitis B and immune response to hepatitis B vaccination in Chinese college students mainly from the rural areas of western China and born before HBV vaccination integrated into expanded program of immunization.</article-title>
<source>Hum Vaccin Immunother</source>. <year>2014</year>;<volume>10</volume>(<issue>1</issue>):<fpage>224</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.4161/hv.26311</pub-id><pub-id pub-id-type="pmid">24018404</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><string-name><surname>Tsukakoshi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Samuela</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rafai</surname>
<given-names>EV</given-names></string-name>, <string-name><surname>Rabuatoka</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Honda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kamiya</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal>
<article-title>Hepatitis B serologic survey and review of immunization records of children, adolescents and adults in Fiji, 2008&#x02013;2009.</article-title>
<source>Virol J</source>. <year>2015</year>;<volume>12</volume>(<fpage>36)</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-015-0267-7</pub-id><pub-id pub-id-type="pmid">25890269</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Qu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal>
<article-title>[Long-term efficacy of neonatal hepatitis B vaccination against chronic hepatitis B virus infection and chronic liver disease: a cross-sectional study based on Qidong Hepatitis B Intervention Study]</article-title>. <source>Zhonghua Liu Xing Bing Xue Za Zhi</source>. <year>2016</year>
<month>1</month>;<volume>37</volume>(<issue>1</issue>):<fpage>64</fpage>&#x02013;<lpage>7</lpage>. <comment>Chinese</comment>.<pub-id pub-id-type="pmid">26822645</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><string-name><surname>Ni</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Jan</surname>
<given-names>CF</given-names></string-name>, <string-name><surname>Hsu</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>HL</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>JF</given-names></string-name>, <etal>et al.</etal>
<article-title>Continuing decrease in hepatitis B virus infection 30 years after&#x000a0;initiation of infant vaccination program in Taiwan.</article-title>
<source>Clin Gastroenterol Hepatol</source>. <year>2016</year>
<month>9</month>;<volume>14</volume>(<issue>9</issue>):<fpage>1324</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.cgh.2016.04.030</pub-id><pub-id pub-id-type="pmid">27155556</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zeng</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Ye</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal>
<article-title>Prevalence of hepatitis B surface antigen (HBsAg) in a blood donor population born prior to and after implementation of universal HBV vaccination in Shenzhen, China.</article-title>
<source>BMC Infect Dis</source>. <year>2016</year>
<month>9</month>
<day>20</day>;<volume>16</volume>(<issue>1</issue>):<fpage>498</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-016-1834-2</pub-id><pub-id pub-id-type="pmid">27647214</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><string-name><surname>Leuridan</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Van Damme</surname>
<given-names>P</given-names></string-name>. <article-title>Hepatitis B and the need for a booster dose.</article-title>
<source>Clin Infect Dis</source>. <year>2011</year>
<month>7</month>
<day>1</day>;<volume>53</volume>(<issue>1</issue>):<fpage>68</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir270</pub-id><pub-id pub-id-type="pmid">21653306</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="web">Hepatitis B 3rd dose (HepB3) immunization coverage [internet]. Geneva: World Health Organization; 2017. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/gho/immunization/hepatitis/en/">http://www.who.int/gho/immunization/hepatitis/en/</ext-link> [cited 2017 Jul 26].</mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="web">Practices to improve coverage of the hepatitis B birth dose vaccine. Geneva: World Health Organization; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/immunization/documents/control/who_ivb_12.11/en/">http://www.who.int/immunization/documents/control/who_ivb_12.11/en/</ext-link> [cited 2018 May 8].</mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><string-name><surname>Schillie</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Walker</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Veselsky</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Crowley</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dusek</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lazaroff</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Outcomes of infants born to women infected with hepatitis B.</article-title>
<source>Pediatrics</source>. <year>2015</year>
<month>5</month>;<volume>135</volume>(<issue>5</issue>):<fpage>e1141</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2014-3213</pub-id><pub-id pub-id-type="pmid">25896839</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="book"><string-name><surname>Van Damme</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Shouval</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Wiersma</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zanetti</surname>
<given-names>A</given-names></string-name>. <chapter-title>Chapter 15</chapter-title>: <chapter-title>Hepatitis B vaccines.</chapter-title> In: <string-name><surname>Plotkin</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Orenstein</surname>
<given-names>WA</given-names></string-name>, <string-name><surname>Offit</surname>
<given-names>PA</given-names></string-name>, editors. <source>Vaccines.</source>
<edition>6th ed.</edition>
<publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Saunders Elsevier</publisher-name>; <year>2012</year> pp. <fpage>205</fpage>&#x02013;<lpage>34</lpage>.</mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><string-name><surname>Cassidy</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mossman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Olivieri</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ridder</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Leroux-Roels</surname>
<given-names>G</given-names></string-name>. <article-title>Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity.</article-title>
<source>Expert Rev Vaccines</source>. <year>2011</year>
<month>12</month>;<volume>10</volume>(<issue>12</issue>):<fpage>1709</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1586/erv.11.151</pub-id><pub-id pub-id-type="pmid">22085174</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><string-name><surname>Dent</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Selvey</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Bell</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Davis</surname>
<given-names>J</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>MI</given-names></string-name>. <article-title>Incomplete protection against hepatitis B among remote Aboriginal adolescents despite full vaccination in infancy.</article-title>
<source>Commun Dis Intell Q Rep</source>. <year>2010</year>
<month>12</month>;<volume>34</volume>(<issue>4</issue>):<fpage>435</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21413528</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><string-name><surname>Griffiths</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Reeve</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Marley</surname>
<given-names>JV</given-names></string-name>. <article-title>Hepatitis B notifications in a vaccinated cohort of Aboriginal people in the Kimberley region.</article-title>
<source>Med J Aust</source>. <year>2014</year>
<month>9</month>
<day>15</day>;<volume>201</volume>(<issue>6</issue>):<fpage>343</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="pmid">25222459</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><string-name><surname>Hanna</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Faoagali</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Buda</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Sheridan</surname>
<given-names>JW</given-names></string-name>. <article-title>Further observations on the immune response to recombinant hepatitis B vaccine after administration to aboriginal and Torres Strait Island children.</article-title>
<source>J Paediatr Child Health</source>. <year>1997</year>
<month>2</month>;<volume>33</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1754.1997.tb00994.x</pub-id><pub-id pub-id-type="pmid">9069048</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><string-name><surname>FitzSimons</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fran&#x000e7;ois</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Hall</surname>
<given-names>A</given-names></string-name>, <string-name><surname>McMahon</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Meheus</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Zanetti</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants.</article-title>
<source>Vaccine</source>. <year>2005</year>
<month>7</month>
<day>14</day>;<volume>23</volume>(<issue>32</issue>):<fpage>4158</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.03.017</pub-id><pub-id pub-id-type="pmid">15964484</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="web">Hepatitis B: fact sheet [internet]. Geneva: World Health Organization, 2017 Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs204/en/">http://www.who.int/mediacentre/factsheets/fs204/en/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2018 Mar 5].</mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><string-name><surname>Zampino</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Boemio</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sagnelli</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Alessio</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Adinolfi</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Sagnelli</surname>
<given-names>E</given-names></string-name>, <etal>et al.</etal>
<article-title>Hepatitis B virus burden in developing countries.</article-title>
<source>World J Gastroenterol</source>. <year>2015</year>
<month>11</month>
<day>14</day>;<volume>21</volume>(<issue>42</issue>):<fpage>11941</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v21.i42.11941</pub-id><pub-id pub-id-type="pmid">26576083</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><string-name><surname>Nayagam</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Thursz</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sicuri</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Conteh</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wiktor</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Low-Beer</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>Requirements for global elimination of hepatitis B: a modelling study.</article-title>
<source>Lancet Infect Dis</source>. <year>2016</year>
<month>12</month>;<volume>16</volume>(<issue>12</issue>):<fpage>1399</fpage>&#x02013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(16)30204-3</pub-id><pub-id pub-id-type="pmid">27638356</pub-id></mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><string-name><surname>Goldstein</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Hadler</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Bell</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Mast</surname>
<given-names>EE</given-names></string-name>, <string-name><surname>Margolis</surname>
<given-names>HS</given-names></string-name>. <article-title>A mathematical model to estimate global hepatitis B disease burden and vaccination impact.</article-title>
<source>Int J Epidemiol</source>. <year>2005</year>
<month>12</month>;<volume>34</volume>(<issue>6</issue>):<fpage>1329</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1093/ije/dyi206</pub-id><pub-id pub-id-type="pmid">16249217</pub-id></mixed-citation></ref></ref-list></back></article>